<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004857" GROUP_ID="DEPRESSN" ID="613103062715582957" MERGED_FROM="" MODIFIED="2011-11-09 09:53:50 -0500" MODIFIED_BY="Akshya Vasudev" REVIEW_NO="J15" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.2">
<COVER_SHEET MODIFIED="2011-11-09 09:48:46 -0500" MODIFIED_BY="Akshya Vasudev">
<TITLE MODIFIED="2011-10-12 02:38:37 -0400" MODIFIED_BY="Chris Champion">Oxcarbazepine for acute affective episodes in bipolar disorder</TITLE>
<CONTACT>
<PERSON ID="13241" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Akshya</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vasudev</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor in Geriatric Psychiatry</POSITION>
<EMAIL_1>akshya.vasudev@uwo.ca</EMAIL_1>
<EMAIL_2>akshya38@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>University of Western Ontario</DEPARTMENT>
<ORGANISATION>London Health Sciences Centre, Victoria Hospital</ORGANISATION>
<ADDRESS_1>800 Commissioners Road East</ADDRESS_1>
<ADDRESS_2>PO BOX 5010</ADDRESS_2>
<CITY>London</CITY>
<ZIP/>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 519 667 6693</PHONE_1>
<PHONE_2/>
<FAX_1>+1 519 667 6707</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2011-11-09 09:48:46 -0500" MODIFIED_BY="Akshya Vasudev">
<PERSON ID="13241" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Akshya</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vasudev</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor in Geriatric Psychiatry</POSITION>
<EMAIL_1>akshya.vasudev@uwo.ca</EMAIL_1>
<EMAIL_2>akshya38@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>University of Western Ontario</DEPARTMENT>
<ORGANISATION>London Health Sciences Centre, Victoria Hospital</ORGANISATION>
<ADDRESS_1>800 Commissioners Road East</ADDRESS_1>
<ADDRESS_2>PO BOX 5010</ADDRESS_2>
<CITY>London</CITY>
<ZIP/>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 519 667 6693</PHONE_1>
<PHONE_2/>
<FAX_1>+1 519 667 6707</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13181" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Karine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Macritchie</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Research Fellow and Honorary Consultant Psychiatrist</POSITION>
<EMAIL_1>karine.macritchie@googlemail.com</EMAIL_1>
<EMAIL_2>kmacritchie@yahoo.co.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Psychiatry</DEPARTMENT>
<ORGANISATION>University of Edinburgh</ORGANISATION>
<ADDRESS_1>Royal Edinburgh Hospital</ADDRESS_1>
<ADDRESS_2/>
<CITY>Edinburgh</CITY>
<ZIP>EH10 5HF</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7570814382E26AA201E6E48B71C94FA3" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kamini</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vasudev</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>kaminivasudev@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>University of Western Ontario</DEPARTMENT>
<ORGANISATION>London Health Sciences Centre, Victoria Hospital</ORGANISATION>
<ADDRESS_1>800 Commissioners Road East</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>PO BOX 5010</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13243" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Stuart</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Watson</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>stuart.watson@newcastle.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Psychiatry, Leazes Wing</DEPARTMENT>
<ORGANISATION>Royal Victoria Infirmary</ORGANISATION>
<ADDRESS_1>Queen Victoria Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Newcastle-upon-Tyne</CITY>
<ZIP>NE1 4LP</ZIP>
<REGION>Tyne and Wear</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>0191 227 5272</PHONE_1>
<PHONE_2/>
<FAX_1>0191 227 5108</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7496" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>John</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Geddes</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Clinical Research Fellow and Professor of Epidemiological Psychiatry, Honorary Consultant Psychiatrist Oxford Mental Healthcare NHS Trust</POSITION>
<EMAIL_1>john.geddes@psych.ox.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Psychiatry</DEPARTMENT>
<ORGANISATION>University of Oxford/Warneford Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Oxford</CITY>
<ZIP>OX3 7JX</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 226480</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1865 793101</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13259" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Allan</FIRST_NAME>
<MIDDLE_INITIALS>H</MIDDLE_INITIALS>
<LAST_NAME>Young</LAST_NAME>
<SUFFIX/>
<POSITION>Chair in Psychiatry</POSITION>
<EMAIL_1>a.young@imperial.ac.uk</EMAIL_1>
<EMAIL_2>allanyoun@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Experimental Medicine, Centre for Mental Health</DEPARTMENT>
<ORGANISATION>Imperial College London</ORGANISATION>
<ADDRESS_1>St Dunstan's Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>W6 8RP</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>020 7386 1233</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-11-01 03:55:44 -0400" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="2" MONTH="9" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="9" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="2" MONTH="9" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2010-12-15 03:47:12 -0500" MODIFIED_BY="Chris Champion"/>
<HISTORY/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Stanley Medical Research Institute</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-11-09 09:53:50 -0500" MODIFIED_BY="Chris Champion">
<SUMMARY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-12-15 03:46:31 -0500" MODIFIED_BY="Chris Champion">Oxcarbazepine for acute affective episodes of bipolar disorder</TITLE>
<SUMMARY_BODY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>People with bipolar disorder suffer from repeated episodes of severe mood disturbance. These can vary from mania to severe depression.  Sometimes manic and depressive symptoms can occur at the same time. Episodes may also fluctuate frequently, so-called 'rapid-cycling'. Periods of normal mood and function may occur in between these episodes, but this is not always the case.</P>
<P>Medications are used to treat these mood episodes and to prevent their recurrence. Oxcarbazepine could be one such medication. Currently, it is only licensed for the treatment of epilepsy.</P>
<P>In this review we found seven studies that were eligible for inclusion, of which four studies compared the efficacy of oxcarbazepine to placebo or to other medications used in treating mania. While there was no evidence that oxcarbazepine worked better compared to a placebo, it did have similar efficacy to more accepted medications for the treatment of the illness.</P>
<P>Two studies examined its acceptability to participants. Oxcarbazepine may cause more side effects than placebo. No differences in side effects were found between oxcarbazepine and other active medications.</P>
<P>All the studies examined mania, hypomania, mixed episodes or rapid-cycling disorder. More studies of better methodological quality are needed if we are to be certain whether oxcarbazepine works or not when treating mania, mixed episodes, depression and rapid-cycling in bipolar disorder. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-11-08 15:03:07 -0500" MODIFIED_BY="Chris Champion">
<ABS_BACKGROUND MODIFIED="2011-08-06 06:38:13 -0400" MODIFIED_BY="[Empty name]">
<P>Oxcarbazepine, a keto derivative of the &#8216;mood stabiliser&#8217; carbamazepine, may have efficacy in the treatment of acute episodes of bipolar disorder. Potentially, it may offer pharmacokinetic advantages over carbamazepine.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-08-06 06:37:33 -0400" MODIFIED_BY="[Empty name]">
<P>To review the efficacy and acceptability of oxcarbazepine compared to placebo and other agents in the treatment of acute bipolar episodes including mania, mixed episodes and depression.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-10-31 12:37:05 -0400" MODIFIED_BY="[Empty name]">
<P>Electronic databases were searched up to 2 September 2011. Specialist journals and conference proceedings were handsearched. Authors, experts in the field and pharmaceutical companies were contacted requesting information on published and unpublished trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-09-28 07:59:15 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) which compared oxcarbazepine with placebo or alternative agents, where the stated intent of intervention was the acute treatment of bipolar affective disorder were sought. Participants with bipolar disorder of either sex and of all ages were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-11-08 15:00:39 -0500" MODIFIED_BY="Chris Champion">
<P>Data were extracted from the original reports individually by two review authors. For dichotomous data, odds ratios (ORs) were calculated with 95% confidence intervals (CI). Continuous data were analysed using standardised mean differences (with 95% CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-11-08 15:03:07 -0500" MODIFIED_BY="Chris Champion">
<P>Seven studies were included in the analysis (368 participants in total). All were on mania, hypomania, mixed episodes or rapid-cycling disorder. Overall, their methodological quality was relatively low.</P>
<P>There was no difference in the primary outcome analysis &#8211; a fall of  50% or more on the Young Mania Rating Scale (YMRS) - between oxcarbazepine and placebo (N=1, n=110, OR =2.10, 95% CI 0.94 to 4.73) in one study, conducted in children; no studies were available in adult participants.</P>
<P>In comparison with other mood stabilisers, there was no difference between oxcarbazepine and valproate as an antimanic agent using the primary outcome (50% or more fall in YMRS, OR=0.44, 95% CI 0.10 to 1.97, 1 study, n=60, P=0.273) or the secondary outcome measure (differences in YMRS between the two groups, SMD=0.18, 95% CI -0.24 to 0.59, 2 studies, n=90, P=0.40). No primary or secondary efficacy outcome measures were found comparing oxcarbazepine with lithium monotherapy.</P>
<P>As an adjunctive treatment to lithium, oxcarbazepine reduced depression rating scale scores more than carbamazepine in a group of manic participants on the Montgomery-Åsberg Depression Rating Scale (MADRS) (SMD=- 1.12, 95% CI -1.71 to -0.53, 1 study, n=52, P=0.0002) and on the Hamilton Depression Rating Scale (HDRS) (SMD=- 0.77, 95% CI -1.35 to -0.20, 1 study, n=52, P=0.008).</P>
<P>There was a higher incidence of adverse effects, particularly neuropsychiatric, in participants randomised to oxcarbazepine compared to those on placebo (1 study, n=115, 17% to 39% of participants on oxcarbazepine had at least one such event compared to 7% to 10% on placebo).There was no difference in adverse events rates between oxcarbazepine and other mood stabilisers or haloperidol.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Currently, there are insufficient trials of adequate methodological quality on oxcarbazepine in the acute treatment of bipolar disorder to inform us on its efficacy and acceptability. Studies predominantly examine the treatment of mania: there are data from subgroup analysis on mixed affective, hypomania and rapid-cycling states.</P>
<P>From the few studies included in this review, oxcarbazepine did not differ in efficacy compared to placebo in children and adolescents. It did not differ from other active agents in adults. It may have a poorer tolerability profile compared to placebo. No data were found on outcomes relevant to patients and clinicians, such as length of hospital admission.  </P>
<P>There is a need for adequately powered randomised controlled trials of good methodological quality to inform us of the therapeutic potential of oxcarbazepine across the spectrum of acute episodes in bipolar disorder.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-11-08 16:10:25 -0500" MODIFIED_BY="Chris Champion">
<BACKGROUND MODIFIED="2011-11-08 15:15:44 -0500" MODIFIED_BY="Chris Champion">
<CONDITION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Bipolar affective disorder is a chronic disorder with a lifetime prevalence of 1 to 5% (<LINK REF="REF-Akiskal-2000" TYPE="REFERENCE">Akiskal 2000</LINK>). Classically, it takes the form of recurrent manic, depressed or mixed episodes with complete inter-episode recovery. However, one third of patients suffer chronic symptoms leading to marked social and occupational impairment.</P>
<P>Mood stabilisers are used in the treatment of bipolar disorder. Ideally, they should treat affective episodes of all forms.</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-11-08 15:07:39 -0500" MODIFIED_BY="Chris Champion">
<P>Lithium is the mood stabiliser in longest use. However, the response to lithium treatment is often unsatisfactory<B>
<I> </I>
</B>(<LINK REF="REF-Bowden-1996" TYPE="REFERENCE">Bowden 1996</LINK>). It has a narrow margin of safety and is often associated with adverse effects, even at therapeutic doses. Its withdrawal precipitates episode recurrence (<LINK REF="REF-Suppes-1991" TYPE="REFERENCE">Suppes 1991</LINK>).</P>
<P>The anticonvulsant valproate has become established as an alternative and adjunctive treatment to lithium as well as for the treatment of acute mania but its use in women of child-bearing age is problematic<B> </B>(<LINK REF="REF-Goodwin-2009" TYPE="REFERENCE">Goodwin 2009</LINK>). The anticonvulsant carbamazepine, has early anti-manic efficacy (<LINK REF="REF-Weisler-2006" TYPE="REFERENCE">Weisler 2006</LINK>). Several atypical antipsychotics have anti-manic activity without the extra pyramidal adverse effects associated with the typicals (<LINK REF="REF-Keck-2000" TYPE="REFERENCE">Keck 2000</LINK>)<B>
<I> </I>
</B>and are now recommended for use in mania (<LINK REF="REF-Goodwin-2009" TYPE="REFERENCE">Goodwin 2009</LINK>)<B>.</B> However, even with these advances, treatment resistance persists, especially in bipolar depression: new medications are required.</P>
<P>Oxcarbazepine is an anticonvulsant indicated for use as single agent therapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as an adjunctive treatment for partial seizures in children (<LINK REF="REF-Beydoun-2002" TYPE="REFERENCE">Beydoun 2002</LINK>). Several studies have suggested efficacy of the drug in affective disorders (<LINK REF="REF-Hellewell-2002" TYPE="REFERENCE">Hellewell 2002</LINK>; <LINK REF="STD-Emrich-1985" TYPE="STUDY">Emrich 1985</LINK>; <LINK REF="REF-Muller-1984" TYPE="REFERENCE">Muller 1984</LINK>; <LINK REF="STD-Munoz-2002" TYPE="STUDY">Munoz 2002</LINK>; <LINK REF="STD-Hummel-2002" TYPE="STUDY">Hummel 2002</LINK>; <LINK REF="STD-Ghaemi-2002" TYPE="STUDY">Ghaemi 2002</LINK>).</P>
<P>The most frequent adverse effects of oxcarbazepine include dizziness, sedation and blurred vision (<LINK REF="REF-Dietrich-2001" TYPE="REFERENCE">Dietrich 2001</LINK>)<B>
<I>. </I>
</B>Rash is less commonly reported with oxcarbazepine compared to carbamazepine; however 25 to 30% of patients with hypersensitivity to carbamazepine are also hypersensitive to oxcarbazepine (<LINK REF="REF-Dietrich-2001" TYPE="REFERENCE">Dietrich 2001</LINK>)<B>
<I>. </I>
</B>The potential for this molecule to induce other serious non-dose related reactions (associated with carbamazepine including agranulocytosis, hepatic reactions, and aplastic anaemia) is considered to be lower.<B>
<I> </I>
</B>However, hyponatremia has been reported in a number of patients treated with oxcarbazepine and the maximum risk has been reported in the first 12 weeks of treatment (<LINK REF="REF-PDR-2001" TYPE="REFERENCE">PDR 2001</LINK>)<B>
<I>. </I>
</B>Recent studies suggest that the risk of hyponatremia may be greater with oxcarbazepine compared to carbamazepine; this is particularly greater in the older than the younger population, and greater in individuals with baseline hyponatremia (<LINK REF="REF-Dong-2005" TYPE="REFERENCE">Dong 2005</LINK>)<B>
<I>.</I>
</B>
</P>
<P>Oxcarbazepine is an analogue of carbamazepine. However, it has a distinct  metabolic profile. It is rapidly converted to its active metabolite 10, 11 - dihydro- 10- hydroxy carbamazepine (MHD). Neither oxcarbazepine nor its metabolite, MHD, induce major hepatic oxidative metabolism and so unlike carbamazepine, oxcarbazepine has few drug interactions (<LINK REF="REF-Isojarvi-1994" TYPE="REFERENCE">Isojarvi 1994</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>The antimanic and antidepressant mechanisms of oxcarbazepine are unclear. Oxcarbazepine, its MHD metabolite and carbamazepine inhibit the influx of sodium into nerve cells and enhance potassium channel opening, processes known to reduce the transmission of nerve impulses.</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-11-08 15:15:44 -0500" MODIFIED_BY="Chris Champion">
<P>The Cochrane Collaboration and specifically the Cochrane Collaboration Depression, Anxiety and Neurosis Review Group (CCDAN) has performed a number of reviews on various anticonvulsants in the treatment of various phases of bipolar disorder (<LINK REF="REF-Macritchie-2009" TYPE="REFERENCE">Macritchie 2009</LINK>; <LINK REF="REF-Vasudev-2009" TYPE="REFERENCE">Vasudev 2009</LINK>; <LINK REF="REF-Vasudev-2009a" TYPE="REFERENCE">Vasudev 2009a</LINK>; <LINK REF="REF-Young-2006" TYPE="REFERENCE">Young 2006</LINK>). Such reviews are an attempt to better inform the management of this disabling condition . Oxcarbazepine may also be efficacious and its metabolic profile may offer practical clinical advantages. Through this review we critically examined its efficacy and safety in the management of acute episodes of bipolar disorder.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>To determine the efficacy and safety of oxcarbazepine</P>
<P>1. compared to placebo or an alternative drug</P>
<P>2. as a comparator or as an additional agent for further augmentation </P>
<P>in treating acute episodes of bipolar disorder</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-11-08 15:19:36 -0500" MODIFIED_BY="Chris Champion">
<SELECTION_CRITERIA MODIFIED="2011-11-08 15:19:36 -0500" MODIFIED_BY="Chris Champion">
<CRIT_STUDIES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials comparing oxcarbazepine in the treatment of acute affective episodes (manic, mixed affective or depressive episodes) with placebo or alternative drug treatment in bipolar affective disorder were sought.</P>
<P>We excluded quasi-randomised studies, such as those allocating participants by using alternate days of the week.</P>
<P>We also excluded cross-over studies where participants receive different treatments sequentially, because of potential carry-over effects from all treatments.</P>
<P>Cluster randomised controlled trials were to be included, whilst being aware of the potential for unit-of-analysis errors (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-10-15 06:33:21 -0400" MODIFIED_BY="[Empty name]">
<P>Trials involving males and females of all ages with a diagnosis of bipolar affective disorder approximating to International Classification of Diseases-10 (ICD-10) Code F31* (<LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>) and/or Diagnostic and Statistical Manual (DSM IV) 296* (<LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>), were included. (This definition of diagnosis included previous versions of ICD and DSM). Please refer to <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for further description of the included codes.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Experimental intervention</HEADING>
<P>Oxcarbazepine in the treatment of acute manic, mixed affective or depressive episodes in the context of bipolar disorder, where acute treatment was defined as treatment instituted specifically to alleviate symptoms of an existing acute episode. Discontinuation trials, in which some participants who had received oxcarbazepine prior to randomisation were switched to placebo, were to be analysed separately because of the unknown risk of recurrence precipitation in this group. In trials combining acute and maintenance treatment, data from acute treatment were to be extracted, if possible. Oxcarbazepine could have been used as a new comparator or as an additional agent for further augmentation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparator interventions</HEADING>
<OL>
<LI>placebo</LI>
<LI>alternative mood stabiliser treatment e.g. lithium, carbamazepine, valproate</LI>
<LI>combination mood stabiliser treatment, or</LI>
<LI>other drug treatments, e.g. antipsychotics like haloperidol</LI>
</OL>
<P>No restriction on dose frequency or dosage were applied.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-11-08 15:19:36 -0500" MODIFIED_BY="Chris Champion">
<P>For each type of episode (acute manic, mixed affective or depressive) a separate analysis was conducted according to the criteria listed. All outcome measures were evaluated by estimating changes from baseline to the end of the study period.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>The following were taken as primary outcomes:</P>
<P>1. the number of participants with mania responding to treatment evidenced by a 50% or greater fall in a mania rating scale (e.g. Young Mania Rating Scale, YMRS (<LINK REF="REF-Young-1978" TYPE="REFERENCE">Young 1978</LINK>), Bech and Rafaelsen Mania Rating Scale, BRMAS (<LINK REF="REF-Bech-1979" TYPE="REFERENCE">Bech 1979</LINK>)), by the end of the study period.</P>
<P>2. the number of depressed participants achieving a 50% or greater fall on a depression rating scale (e.g. Hamilton Depression Rating Scale, HDRS (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>) for participants in other acute phases of bipolar disorder by the end of the study period.</P>
<P>3. the number of participants with mixed affective states achieving a 50% or greater fall on a depression or a mania rating scale.</P>
<P>See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for further details of rating scales.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-11-08 15:19:36 -0500" MODIFIED_BY="Chris Champion">
<P>1. For each type of affective episode the following outcome measures were to be estimated:</P>
<P>For manic episodes, efficacy of treatment measured by:</P>
<UL>
<LI>Requirement for hospital admission</LI>
<LI>Length of hospital admission</LI>
<LI>Time to cessation of additional treatment for manic symptoms</LI>
<LI>Scores in manic symptom rating scales</LI>
<LI>Scores in psychotic symptom scales e.g. Brief Psychiatric Rating Scale, BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)</LI>
</UL>
<P>For mixed affective episodes, efficacy of treatment measured by:</P>
<UL>
<LI>Requirement for hospital admission</LI>
<LI>Length of hospital admission</LI>
<LI>Time to cessation of additional treatment for mixed affective symptoms</LI>
<LI>Scores in symptom rating scales</LI>
</UL>
<P>For depressive episodes, efficacy of treatment measured by:</P>
<UL>
<LI>Requirement for hospital admission</LI>
<LI>Length of hospital admission</LI>
<LI>Time to cessation of additional treatment for depressive symptoms</LI>
<LI>Scores in symptom rating scales</LI>
</UL>
<P>2. Psychological, social and occupational functioning as measured by:</P>
<UL>
<LI>Global impression of the clinician e.g. clinical global impression, CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)</LI>
<LI>Global impression of the subject, family or significant others</LI>
</UL>
<P>3. Acceptability of oxcarbazepine treatment, as measured by:</P>
<UL>
<LI>participants dropping out of the treatment during the study period as a proportion of the total number of randomised patients (total drop out rate)</LI>
<LI>participants dropping out due to inefficacy during the trial as a proportion of the total number of randomised patients (drop out rate due to inefficacy)</LI>
<LI>participants' reports of satisfaction or otherwise with treatment</LI>
</UL>
<P>4. Adverse effects:</P>
<P>Participants experiencing:</P>
<UL>
<LI>Troublesome adverse effects of any nature</LI>
</UL>
<P>Then specific adverse effects were considered:</P>
<UL>
<LI>Dizziness</LI>
<LI>Diplopia</LI>
<LI>Somnolence</LI>
<LI>Sleep disturbance</LI>
<LI>Fatigue</LI>
<LI>Nausea</LI>
<LI>Vomiting</LI>
<LI>Ataxia</LI>
<LI>Abnormal Vision</LI>
<LI>Abdominal pain</LI>
<LI>Tremor</LI>
<LI>Dyspepsia</LI>
<LI>Abnormal gait</LI>
</UL>
<P>Rare/serious events were to be reported in the text:</P>
<UL>
<LI>Haematological disturbances</LI>
<LI>Hyponatraemia</LI>
</UL>
<P>5. Mortality Rates:</P>
<UL>
<LI>Overall mortality rates during the study period</LI>
<LI>Mortality excluding suicide and verdicts of undetermined death</LI>
<LI>Mortality due to iatrogenic causes</LI>
<LI>Suicide and verdicts of undetermined death</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>CCDAN's Specialised Register (CCDANCTR)</B>
</P>
<P>The Cochrane Depression, Anxiety and Neurosis Group (CCDAN) maintain two clinical trials registers at their editorial base in Bristol, UK: a references register and a studies based register. The CCDANCTR-References Register contains over 27,500 reports of trials in depression, anxiety and neurosis. Approximately 60% of these references have been tagged to individual, coded trials. The coded trials are held in the CCDANCTR-Studies Register and records are linked between the two registers through the use of unique study ID tags. Coding of trials is based on the EU-Psi coding manual. Please contact the CCDAN Trials Search Co-ordinator for further details.</P>
<P>Reports of trials for inclusion in the Group's registers are collated from routine (weekly), generic searches of MEDLINE (1950 -), EMBASE (1974 -) and PsycINFO (1967 -); quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review-specific searches of additional databases. Reports of trials are also sourced from international trials registers c/o the World Health Organisation&#8217;s trials portal (ICTRP) (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>), drug companies, the handsearching of key journals, conference proceedings and other (non-Cochrane) systematic reviews and meta-analyses.</P>
<P>Details of CCDAN&#8217;s generic search strategies used to identify RCTs can be found on the <A HREF="http://ccdan.cochrane.org/search-strategies-identification-studies">CCDAN website</A>.</P>
<ELECTRONIC_SEARCHES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Searches of the CCDANCTR were conducted by the Trials Search Co-ordinator (TSC) to 2 September 2011 using the following search terms:</P>
<P>CCDANCTR-Studies:<BR/>Intervention = Oxcarbazepine</P>
<P>CCDANCTR-References :<BR/>Free-text = Oxcarbazepin* or Apydan or Trileptal</P>
<P>Earlier searches were also conducted in November 2009 and December 2010.<BR/>In 2009 the CCDANCTR had fallen out-of-date due to a change-over of staff at the editorial base so the TSC ran additional searches on MEDLINE, EMBASE, PsycINFO and the Cochrane Register of Controlled Trials (CENTRAL), see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> (for search strategies used).</P>
<P>The WHO trials portal (<A HREF="http://apps.who.int/trialsearch/Default.aspx">ICTRP</A>) was searched (September 2011) together with the FDA website and Novartis Clinical Trials Register (Dec 2010).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>1) Handsearches<BR/>Appropriate journals and conference proceedings relating to oxcarbazepine treatment for bipolar disorder were handsearched and incorporated into the CCDANCTR. In addition, the authors (AV and KM) performed their own handsearch of the annual conference proceedings of the American Psychiatric Association (2001 to 2011), Collegium Internationale Neuro-Psychopharmacologicum (CINP) (2001 to 2011) and the British Association of Psychopharmacology (2001 to 2011). The authors also performed a handsearch of textbooks on affective disorders including Essential Psychopharmacology of Depression and Bipolar Disorder (<LINK REF="REF-Stahl-2000" TYPE="REFERENCE">Stahl 2000</LINK>), Oxford Textbook of Psychiatry (<LINK REF="REF-Gelder-2003" TYPE="REFERENCE">Gelder 2003</LINK>) and Textbook of Psychopharmacology (<LINK REF="REF-Schatzberg-2004" TYPE="REFERENCE">Schatzberg 2004</LINK>).<BR/>2) Personal communication<BR/>Pharmaceutical companies and experts in this field were asked if they knew of any study which met the inclusion criteria of this review.<BR/>3) Reference checking<BR/>Reference lists of the included studies, previous systematic reviews and major textbooks of affective disorder written in English were checked for published reports and citations of unpublished research.<BR/>
</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-11-08 15:17:14 -0500" MODIFIED_BY="Chris Champion">
<STUDY_SELECTION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Studies relating to oxcarbazepine generated by the electronic search of CCDANCTR were scanned by one review author (AV). The abstracts of these studies were individually read to check if they fulfilled the following preliminary criteria for inclusion:</P>
<P>a) randomised controlled trial</P>
<P>b) comparing oxcarbazepine with a comparator</P>
<P>c) participants with bipolar disorder, of whatever type</P>
<P>Such studies were highlighted for discussion with the second author (KM). After agreement, studies fulfilling above criteria were ordered from the local medical library. All the full text articles from this preliminary list were then assessed by two review authors (AV and KM) independently to see if they met the stricter inclusion criteria for the review. If the raters disagreed the final ratings were made by consensus with the involvement (if necessary) of another member of the author team. Non-congruence in selection of trials was reported as percentage disagreement. Care was taken to avoid duplicating trials by inclusion of multiple papers reporting on the same trial, instead these were linked together as multiple references to the same trial.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-10-14 05:57:24 -0400" MODIFIED_BY="[Empty name]">
<P>Two review authors (AV and KM) independently extracted data concerning participant characteristics (age, sex, bipolar diagnosis, comorbidity, severity of episode, treatment history, study setting), intervention details (intended dosage range, mean daily dosage actually prescribed, co-intervention if any, oxcarbazepine as investigational drug or as comparator drug, sponsorship) and outcome measures of interest from the included studies. Any disagreements were to be resolved by consensus discussions with a third member of the review team.</P>
<P>Non-concurrence in selection and quality assessment were to be reported.</P>
<P>Main Comparisons:</P>
<P>1.       Oxcarbazepine vs placebo</P>
<P>2.       Oxcarbazepine vs alternative mood stabiliser</P>
<P>3.       Oxcarbazepine as an adjunctive mood stabiliser vs alternative mood stabiliser</P>
<P>4.       Oxcarbazepine vs other drug treatments</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>In a change to our published protocol, the methodological quality of the trials was assessed independently by three authors (SW, AHY, KV). In addition, AV and KM conducted independent quality assessment in parallel with the data extraction which they performed.<BR/>The Cochrane Collaboration risk of bias tool was used (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). This instrument consists of six domains:</P>
<UL>
<LI>The first two domains assess the strength of the randomisation process in preventing selection bias in the assignment of participants to interventions: adequacy of sequence generation and allocation concealment</LI>
<LI>The third domain (blinding) assesses the influence of performance bias on the study results</LI>
<LI>The fourth domain assesses the likelihood of incomplete outcome data, which raises the possibility of bias in effect estimates</LI>
<LI>The fifth domain assesses selective reporting, the tendency to preferentially report statistically significant outcomes. It requires a comparison of published data with trial protocols, when such are available</LI>
<LI>The final domain refers to other sources of bias that are relevant in certain circumstances, for example, in relation to trial design (methodological issues such as those related to cross-over designs and early trial termination) or setting</LI>
</UL>
<P>A description of what was reported to have happened in the study was given for each domain, and a judgement relating to the risk of bias was assigned (low risk, unclear risk and high risk of bias). Any disagreements about risk of bias were resolved by AV, in consultation with KM.<BR/>
</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>For dichotomous outcomes the odds ratio was calculated with 95% confidence limits. For continuously distributed outcome data the standardised mean difference (SMD) with 95% confidence limits was used. If the number of trials was fewer than two, event rates were expressed as percentages in the active and comparator groups.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Studies with cross-over design</B>
</P>
<P>Trials with cross-over design were excluded, hence unit of analysis issues did not arise because of this.</P>
<P>
<B>Cluster randomised studies</B>
</P>
<P>No cluster randomised trials were identified for this version of the review. If they were to be identified in a future update, we plan to use the generic inverse variance technique and the intraclass correlation coefficients to adjust for cluster effects using Revman.</P>
<P>
<B>Studies with multiple treatment groups</B>
</P>
<P>No trials were found with multiple treatment groups. If they were to be identified in a future update, we plan to combine all relevant experimental intervention groups of the study into a single group.</P>
<P>
<B>Repeated measurement of same outcome</B>
</P>
<P>To avoid the risk of Type 1 errors due to repeatedly measuring the same outcome over a period of time, we did not conduct such analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Study responders were calculated on an intention-to-treat (ITT) basis; this implies that drop outs were always included in the analysis. Where participants withdrew from the trial before the study endpoint, it was assumed that they would have experienced a negative outcome by the end of the trial (e.g. failure to respond to treatment). Where there were missing data and the method of &#8220;last observation carried forward&#8221; (LOCF) had been used to do an ITT analysis, then the LOCF data were used, with due consideration of the potential bias and uncertainty introduced. When dichotomous or continuous outcomes were not completely reported in the published literature, trial authors were to be asked to supply the data on an individual basis. The results arising from these two methods were to be compared during sensitivity analysis. Where ITT analysis was not possible, endpoint data for trial completers were to be used.</P>
<P>When only the SE or t-statistics or P values were reported, SDs were imputed for changes from baseline as described previously (<LINK REF="REF-Follmann-1992" TYPE="REFERENCE">Follmann 1992</LINK>; <LINK REF="REF-Abrams-2005" TYPE="REFERENCE">Abrams 2005</LINK>)</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-11-08 15:08:18 -0500" MODIFIED_BY="Chris Champion">
<P>Heterogeneity between studies was assessed using the chi<SUP>2</SUP> test of heterogeneity and also by visual inspection of the forest plots as suggested in the Cochrane Handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). A statistical significance value (P) of 0.1 was used for this test. If significant heterogeneity was identified, sources were investigated. Potential sources include the presence of schizoaffective and unipolar groups in the study sample, variation in dose and duration of treatment, demographic factors and illness characteristics. Any other potential source of heterogeneity which was apparent on examining the studies was also included.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Funnel plots were to be used to determine publication bias. We would have used the test for funnel plot asymmetry (Egger's test) only when there were at least 10 studies included in the meta-analysis. However, as the number of included studies were few, it was not attempted as recommended by the Cochrane Handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-11-08 15:17:14 -0500" MODIFIED_BY="Chris Champion">
<P>Data were entered into Review Manager 5 software by one reviewer (AV).</P>
<P>For the dichotomous outcomes we used a random-effects model OR. This model had the highest generalisability in our empirical examination of summary effect measures for meta-analyses (<LINK REF="REF-Furukawa-2002" TYPE="REFERENCE">Furukawa 2002</LINK>). The robustness of this summary measure was routinely examined by checking the fixed-effect model OR and the random-effects model risk ratio (RR). Material differences between the models, if any, were reported.</P>
<P>For continuous outcomes we used a fixed-effect model SMD. This was routinely examined by comparing with a random-effects model SMD. Similarily if there were material differences between the models we reported them.</P>
<P>When it appeared that the data were skewed, using recommended methods for identifying skewness from summary data (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>), they were reported descriptively. A negative outcome was assumed if participants dropped out of the study for any other reason than response to treatment. Non-quantitative data were to be presented descriptively. Outcomes concerning relapse/recurrence of affective disorder were to be analysed excluding data from studies of discontinuation design. Data from these studies were to be analysed separately, to assess the effects of oxcarbazepine discontinuation.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Subgroup analyses, as recommended by the Cochrane Handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>; <LINK REF="REF-Oxman-1995" TYPE="REFERENCE">Oxman 1995</LINK>) were to be performed as defined a priori to assess the outcomes of oxcarbazepine treatment for:</P>
<P>1. mixed affective episodes</P>
<P>2. affective disorder with psychotic features, and</P>
<P>3. schizoaffective disorder</P>
<P>Where such separation was impossible, the studies were to be included but a sensitivity analysis was to be conducted to examine the effect of their inclusion on the results. If such separation of heterogenous group data proved impossible, it was planned to extract information from these studies only if at least 80% of randomised participants had a bipolar diagnosis.</P>
<P>Subgroup analyses were also to be performed to assess the effectiveness of oxcarbazepine treatment in previous mood stabiliser non-responders.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-04-03 08:30:13 -0400" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses were to be performed for the following</P>
<UL>
<LI>Excluding trials at high risk of bias</LI>
<LI>Excluding trials with more than 50% non-completers</LI>
<LI>Excluding trials where results have been reported using LOCF</LI>
<LI>Analysis based on available cases rather than ITT</LI>
</UL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-11-08 16:10:22 -0500" MODIFIED_BY="Chris Champion">
<STUDY_DESCRIPTION MODIFIED="2011-11-08 16:10:22 -0500" MODIFIED_BY="Chris Champion">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>; <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>
</P>
<SEARCH_RESULTS MODIFIED="2011-11-08 15:28:08 -0500" MODIFIED_BY="Chris Champion">
<P>A search of the CCDANCTR together with MEDLINE, EMBASE, PsycINFO and CENTRAL (November 2009) revealed 186 references which could be considered for inclusion.</P>
<P>We found seven studies (including 368 participants) which met the screening criteria for inclusion. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for a schematic representation of the screening procedure.</P>
<P>Two authors (AV and KM) agreed that four of these studies met the inclusion criteria for this review and meta-analysis (<LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>; <LINK REF="STD-Kakkar-2009" TYPE="STUDY">Kakkar 2009</LINK>; <LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>; <LINK REF="STD-Wagner-2006" TYPE="STUDY">Wagner 2006</LINK>). The three older studies (<LINK REF="STD-Emrich-1990" TYPE="STUDY">Emrich 1990</LINK>; <LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK>; <LINK REF="STD-Mueller-1984b" TYPE="STUDY">Mueller 1984b</LINK>) which were similar in design and quality, were not utilised for the purposes of meta-analysis of the efficacy data due to lack of clarity in the reporting results. Safety data was described with adequate clarity in two of these studies<B>
<I> </I>
</B>(<LINK REF="STD-Emrich-1990" TYPE="STUDY">Emrich 1990;</LINK> <LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK>) to allow extraction. Details of these studies are given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>An update search of the CCDANCTR was performed (December 2010, September 2011) and revealed four new studies. Only one study (<LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>) met the inclusion criteria and this study had already been included.</P>
<P>All conference proceedings as listed above in the handsearch section were searched between March 2010 and September 2011. No studies were found from the handsearches. All the text books as listed above in the handsearch section were also searched between March 2010 and September 2011. No new references were found.</P>
<P>Novartis Pharmaceuticals was contacted on the 17 March 2010 regarding further details of their New Drug Application (NDA) application in 1997 of oxcarbazepine in the treatment of epilepsy. This document also mentions a small, placebo controlled trial for mania which was of two days duration and was terminated due to slow enrolment. Further details of this trial are awaited.</P>
<P>The WHO trials portal (ICTRP), searched in September 2011, revealed one ongoing study from the Iranian Clinical Trials Registry <LINK REF="STD-IRCT201012055280N2" TYPE="STUDY">IRCT201012055280N2</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>As mentioned above, a total of seven studies were included in the review (<LINK REF="STD-Emrich-1990" TYPE="STUDY">Emrich 1990</LINK>; <LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK>; <LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>; <LINK REF="STD-Kakkar-2009" TYPE="STUDY">Kakkar 2009</LINK>; <LINK REF="STD-Mueller-1984b" TYPE="STUDY">Mueller 1984b</LINK>; <LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>; <LINK REF="STD-Wagner-2006" TYPE="STUDY">Wagner 2006</LINK>) Attempts to contact authors for additional information was successful in only three cases (<LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>; <LINK REF="STD-Kakkar-2009" TYPE="STUDY">Kakkar 2009</LINK>; <LINK REF="STD-Wagner-2006" TYPE="STUDY">Wagner 2006</LINK>).</P>
<P>
<B>Sample Size</B>
</P>
<P>All studies had relatively small sample sizes: only one study recruited more than 100 participants (<LINK REF="STD-Wagner-2006" TYPE="STUDY">Wagner 2006</LINK>).</P>
<P>
<B>Study Design</B>
</P>
<P>All included studies were randomised controlled trials.</P>
<P>
<B>Setting/Participants</B>
</P>
<P>All included studies used standardised methods for diagnosis of bipolar illness including DSM-III, DSM-IV and SADS-L. All studies, except one, were conducted in the adult population; though this was not always explicitly described in the text. One study was carried out in children and adolescents (<LINK REF="STD-Wagner-2006" TYPE="STUDY">Wagner 2006</LINK>).</P>
<P>
<B>Interventions and Comparators</B>
</P>
<P>Studies compared oxcarbazepine with other compounds including one study versus placebo (<LINK REF="STD-Wagner-2006" TYPE="STUDY">Wagner 2006</LINK>), two versus haloperidol (<LINK REF="STD-Emrich-1990" TYPE="STUDY">Emrich 1990</LINK>, <LINK REF="STD-Mueller-1984b" TYPE="STUDY">Mueller 1984b</LINK>), one versus lithium (<LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK>), two versus valproate (<LINK REF="STD-Kakkar-2009" TYPE="STUDY">Kakkar 2009</LINK>; <LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>) and one versus carbamazepine (<LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>). In all but one study, oxcarbazepine or comparator was used as the only mood stabiliser for treatment of acute bipolar episodes. However, in one study (<LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>) the two groups had been previously maintained on lithium and had suffered a relapse of the illness prior to randomisation.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-11-08 16:10:22 -0500" MODIFIED_BY="[Empty name]">
<P>One hundred and eighty-six references were found based on the search results (CCDANCTR, MEDLINE, EMBASE, PsycINFO and CENTRAL (November 2009)). From these we excluded 129 based on the initial title and abstract screening. There was no disagreement between the authors (AV and KM) for their exclusion. Fifty-seven articles were procured for full text checking. From these we found 40 studies: 37 were in English, one in German, one in Spanish and one in Portugese. Online language translation software (Google.com) was used for cross-checking the references in these non-English reviews for any potentially includable study; none was found.</P>
<P>We excluded 50 studies for various reasons, 41 of these have been described in more detail as per characteristics of excluded studies (nine were not described in the table as they did not trial oxcarbazepine in acute bipolar disorder). The highest frequency of cause for exclusion was open-label design in 14 studies (<LINK REF="STD-Conway-2003" TYPE="STUDY">Conway 2003;</LINK> <LINK REF="STD-Conway-2006" TYPE="STUDY">Conway 2006;</LINK> <LINK REF="REF-Davanzo-2004" TYPE="REFERENCE">Davanzo 2004</LINK>, <LINK REF="STD-Deutschman-2003" TYPE="STUDY">Deutschman 2003</LINK>; <LINK REF="STD-Greil-1985" TYPE="STUDY">Greil 1985</LINK>; <LINK REF="STD-Kouzavkova-1996" TYPE="STUDY">Kouzavkova 1996</LINK>; <LINK REF="STD-Lattanzi-2003" TYPE="STUDY">Lattanzi 2003</LINK>; <LINK REF="STD-Mueller-1983" TYPE="STUDY">Mueller 1983</LINK>; <LINK REF="STD-Munoz-2002" TYPE="STUDY">Munoz 2002</LINK>; <LINK REF="STD-Norton-2001" TYPE="STUDY">Norton 2001</LINK>; <LINK REF="STD-Reinstein-2003" TYPE="STUDY">Reinstein 2003</LINK>; <LINK REF="STD-Schaffer-2003" TYPE="STUDY">Schaffer 2003</LINK>; <LINK REF="STD-Tavormina-2000" TYPE="STUDY">Tavormina 2000</LINK>; <LINK REF="STD-Velikonja-1984" TYPE="STUDY">Velikonja 1984</LINK>) followed by retrospective chart review in nine studies (<LINK REF="STD-Ghaemi-2002" TYPE="STUDY">Ghaemi 2002</LINK>; <LINK REF="STD-Ghaemi-2003" TYPE="STUDY">Ghaemi 2003</LINK>; <LINK REF="STD-MacMillan-2006" TYPE="STUDY">MacMillan 2006</LINK>; <LINK REF="STD-Misdrahi-2008" TYPE="STUDY">Misdrahi 2008</LINK>; <LINK REF="STD-Nasr-2003" TYPE="STUDY">Nasr 2003</LINK>; <LINK REF="STD-Platt-2003" TYPE="STUDY">Platt 2003</LINK>; <LINK REF="STD-Pratoomsri-2005" TYPE="STUDY">Pratoomsri 2005</LINK>; <LINK REF="STD-Raja-2003" TYPE="STUDY">Raja 2003</LINK>; <LINK REF="STD-Salpekar-2006" TYPE="STUDY">Salpekar 2006</LINK>), and case reports in four studies (<LINK REF="STD-Kalra-2006" TYPE="STUDY">Kalra 2006</LINK>; <LINK REF="STD-Majczenko-2007" TYPE="STUDY">Majczenko 2007</LINK>; <LINK REF="STD-Nasr-2002" TYPE="STUDY">Nasr 2002</LINK>; <LINK REF="STD-Teitelbaum-2001" TYPE="STUDY">Teitelbaum 2001</LINK>). There were three studies which had poor randomised control design preventing them from inclusion in this review: <LINK REF="STD-Emrich-1983" TYPE="STUDY">Emrich 1983</LINK> and <LINK REF="STD-Emrich-1985" TYPE="STUDY">Emrich 1985</LINK> used an A-B-A design (new treatment followed by old treatment and then new treatment in the same patient) while <LINK REF="STD-Hummel-2002" TYPE="STUDY">Hummel 2002</LINK> used an on-off-on design. One study did not describe the methodology clearly; <LINK REF="STD-Mueller-1984" TYPE="STUDY">Mueller 1984</LINK> described "5 trials" of oxcarbazepine. We could not ascertain if this was a review or a series of case reports. One study was considered too short a duration of treatment (<LINK REF="STD-NDA-application-1997" TYPE="STUDY">NDA application 1997</LINK>). Four studies used oxcarbazepine in a maintenance fashion (<LINK REF="STD-Mosolov-2009" TYPE="STUDY">Mosolov 2009</LINK>; <LINK REF="STD-Rosa-2009" TYPE="STUDY">Rosa 2009</LINK>; <LINK REF="STD-Vieta-2008" TYPE="STUDY">Vieta 2008</LINK>; <LINK REF="STD-Wildgrube-1990" TYPE="STUDY">Wildgrube 1990</LINK>).</P>
<P>
<B>Ongoing studies</B>
</P>
<P>One study is currently ongoing. See <LINK TAG="ONGOING_STUDIES" TYPE="SECTION">Ongoing studies</LINK>.</P>
<P>
<B>Studies awaiting classification</B>
</P>
<P>We have no studies that are still awaiting classification</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-11-08 15:19:52 -0500" MODIFIED_BY="Chris Champion">
<P>Studies did not describe risk of bias issues with sufficient clarity in the published literature. Three study authors were able to clarify risk of bias issues which had a positive impact on their quality assessment. However, overall the quality of studies was low (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>For review of the authors' assessment of risk of bias of individual items for the included studies please see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Generally, more recently published studies provided better descriptions of their method of allocation to treatment groups (<LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>; <LINK REF="STD-Kakkar-2009" TYPE="STUDY">Kakkar 2009</LINK>; <LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>; <LINK REF="STD-Wagner-2006" TYPE="STUDY">Wagner 2006</LINK>). Amongst these, computer-generated randomisation sequences were most commonly used.</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-08-06 11:48:32 -0400" MODIFIED_BY="[Empty name]">
<P>Most studies were described as double blind except one which was single blind (<LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>). However, in studies where double blinding was mentioned, it was not clear whether this related to the blinding of patient, treating clinician or assessor.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-11-08 15:19:52 -0500" MODIFIED_BY="Chris Champion">
<P>Two studies (<LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>; <LINK REF="STD-Wagner-2006" TYPE="STUDY">Wagner 2006</LINK>) had clear methods of incorporating incomplete outcome data within the results. <LINK REF="STD-Kakkar-2009" TYPE="STUDY">Kakkar 2009</LINK> reports that all the included participants completed all the outcome data. <LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>, <LINK REF="STD-Emrich-1990" TYPE="STUDY">Emrich 1990</LINK> and <LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK> do not report with adequate clarity how incomplete data were handled. We were unable to contact the study authors for clarification.</P>
<P>We could not perform a sensitivity analysis of the effect of inclusion of missing outcome data as we were unable to obtain specific individual missing data from the trial authors.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>We were unable to obtain the trial protocols of the included studies. Hence, we were unable to ascertain if the study authors had selectively reported positive outcomes in the published manuscript and desisted from reporting negative ones. This could have led to bias of selective reporting, as suggested in the Cochrane Handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
<P>In addition, the quality of older published studies was generally poorer as they did not describe outcome measures in the materials and methods section a priori (<LINK REF="STD-Emrich-1990" TYPE="STUDY">Emrich 1990</LINK>; <LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK>). More recently published studies documented all outcome measures in the results section that they planned to conduct.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-11-08 15:09:58 -0500" MODIFIED_BY="Chris Champion">
<P>One study had a number of methodological deficiencies which could have led to significant bias in the report (<LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>).</P>
<P>
<B>Discontinuation effects</B>
<BR/>It is now accepted that "rebound mania" occurs in some bipolar patients on discontinuation of lithium (<LINK REF="REF-Goodwin-1994" TYPE="REFERENCE">Goodwin 1994</LINK>). In acute treatment trials, discontinuation of lithium prior to the experimental phase might lead to exacerbation of mania, possibly affecting the observed response to the trial drug. It is not clear whether a similar effect exists on anticonvulsant withdrawal, though evidence is emerging for other psychotropics as well (<LINK REF="REF-Franks-2008" TYPE="REFERENCE">Franks 2008</LINK>). None of the trials appeared to have given specific consideration to this phenomenon. One study, <LINK REF="STD-Wagner-2006" TYPE="STUDY">Wagner 2006</LINK>, reports discontinuation and wash out of psychotropic agents prior to randomisation. Stimulants and diphenhydramine were allowed in addition to the trial medication.<BR/>
</P>
<P>
<B>Use of rescue medication and adjustment of dose of investigational drug</B>
<BR/>Several lithium trials have been criticised as the dosage of a trial drug was altered in response to clinical deterioration (<LINK REF="REF-Moncrieff-1997" TYPE="REFERENCE">Moncrieff 1997</LINK>). The included studies in this review do not clearly indicate such dose adjustments. The Emrich studies (<LINK REF="STD-Emrich-1990" TYPE="STUDY">Emrich 1990</LINK>; <LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK>) initiated the mood stabilisers with a predetermined increase in the dosage of oxcarbazepine and the comparator mood stabiliser. <LINK REF="STD-Wagner-2006" TYPE="STUDY">Wagner 2006</LINK> included a two week titration period after randomisation during which the dosage of oxcarbazepine was increased by 300 mg every two days to a maximum dose level of 900-2400 mg/day based on body weight or to the maximum dose tolerated. Change in dosage of oxcarbazepine was not linked to either clinical efficacy or serum drug levels. A dose reduction in oxcarbazepine by 300 mg/day was permitted in the case of intolerable adverse effects. Diphenydramine could be used as a rescue medication to control aggressive behaviour.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-11-08 15:29:12 -0500" MODIFIED_BY="Chris Champion">
<SUBSECTION>
<HEADING LEVEL="3">1. Oxcarbazepine versus Placebo</HEADING>
<P>Only one study contributed to the analysis. This study was performed in children and adolescents with mania (<LINK REF="STD-Wagner-2006" TYPE="STUDY">Wagner 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 PRIMARY OUTCOME MEASURES</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1.1 Number of participants who responded by 50% or more on a mood rating scale</HEADING>
<P>This study provided data using the YMRS<B> </B>(<LINK REF="REF-Young-1978" TYPE="REFERENCE">Young 1978</LINK>). There was no difference in efficacy between oxcarbazepine and placebo in the combined group of children and adolescents (OR=2.10, 95% CI 0.94 to 4.73; P=0.07, 1 study, n=110). However, in the subgroup of children oxcarbazepine was superior to placebo (OR=3.38, 95% CI 1.11 to 10.30; P=0.03, n=69) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 SECONDARY OUTCOME MEASURES</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.2.1 Change in mania and depression ratings scores.</HEADING>
<P>There was no evidence that oxcarbazepine was any different from placebo in treatment of mania (measured by YMRS, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) (SMD =-0.10, 95% CI -0.48 to 0.27, P=0.591, 1 study, n=110) or mixed affective states (CDRS, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) (SMD= -0.15, 95% CI -0.52 to 0.23, P=0.436, 1 study, n=110).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.2 Psychological, social and occupational functioning</HEADING>
<P>There was no evidence that oxcarbazepine was any different from placebo as measured by CGI-S (SMD = -0.20, 95% CI -0.57 to 0.18, P=0.303, 1 study, n=110) and CHQ (global health score (SMD = 0.28, 95% CI -0.10 to 0.66, P=0.142, 1 study, n=110) and global behaviour score (SMD = -0.07, 95% CI -0.44 to 0.31, P=0.724, 1 study, n=110)) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.3 Acceptability: drop out rate</HEADING>
<P>The drop out rate was similar in both the groups (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>), OR=0.68 (95 % CI: 0.32 to 1.46; P = 0.32; 1 study, n = 115).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.4 Adverse effects</HEADING>
<P>See side effects profile by body systems: neuropsychiatric adverse effects occurred more frequently in participants on oxcarbazepine. In particular, dizziness, somnolence and diplopia occurred with frequencies varying from 18 to 40% in the oxcarbazepine group compared to 0 to 10% in the placebo group (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). The authors also provided data on serious psychiatric events leading to admission (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>), there was no evidence that oxcarbazepine was any different from placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.5 Mortality</HEADING>
<P>There was no incidence of mortality in either group.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Oxcarbazepine versus other mood stabilisers</HEADING>
<P>Three studies used oxcarbazepine and the comparator agent in monotherapy. Oxcarbazepine was compared to valproate<B>
<I> </I>
</B>(<LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007;</LINK> <LINK REF="STD-Kakkar-2009" TYPE="STUDY">Kakkar 2009</LINK>), carbamazepine (<LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>) and lithium (<LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK>). Two studies (<LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>; <LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK>) were conducted in the manic or hypomanic phase of bipolar disorder only. <LINK REF="STD-Kakkar-2009" TYPE="STUDY">Kakkar 2009</LINK> included participants with mania, mixed affective episodes and rapid-cycling.</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 PRIMARY OUTCOME MEASURE</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1.1 Number of participants who responded by 50% or more on a mood rating scale</HEADING>
<P>Data on the number of participants who responded by 50% or more on a mood rating scale, was available from only one study for this outcome with valproate as comparator<B>
<I> </I>
</B>(<LINK REF="STD-Kakkar-2009" TYPE="STUDY">Kakkar 2009</LINK>). There was no evidence that oxcarbazepine was either superior or inferior to valproate (OR=0.44, 95% CI 0.10 to 1.97, 1 study, n=60, P=0.273) <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>. No results could be extracted on this outcome from the lithium comparator study (<LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 SECONDARY OUTCOME MEASURE</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.2.1 Fall in mania and depression rating scales</HEADING>
<P>There was no evidence that oxcarbazepine differed from valproate on mean change in YMRS (SMD=0.18, 95% CI -0.24 to 0.59, 2 studies, n=90, P=0.40) <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>. No results could be extracted on this outcome from the lithium study (<LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.2 Psychological, social and occupational functioning</HEADING>
<P>There was no evidence that oxcarbazepine differed from valproate on mean change in CGI-S scores from baseline to endpoint from the results of one study (<LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>) (SMD =-0.49, 95% CI -1.22 to 0.24, P=0.1768, 1 study, n=30) <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>. No results could be extracted from the study with lithium as comparator (<LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.3 Acceptability: drop out rate</HEADING>
<P>Data on this outcome was not available for extraction for the  valproate comparator studies (<LINK REF="STD-Kakkar-2009" TYPE="STUDY">Kakkar 2009</LINK>, <LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>). One study (<LINK REF="STD-Emrich-1990b" TYPE="STUDY">Emrich 1990b</LINK>) assessed the physician's assessment of global tolerability compared to lithium. There was no evidence that oxcarbazepine was any different from lithium <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>, <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.4 Adverse effects</HEADING>
<P>Neuropsychiatric symptoms side effects profiles for oxcarbazepine and comparator agents are listed<B>
<I> </I>
</B>in<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>. Data was available for valproate and lithium from only one study each. Oxcarbazepine did not seem to differ from valproate or lithium on any side effects (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2.5 Mortality</HEADING>
<P>There was no incidence of mortality in any of the treatment groups.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Oxcarbazepine as an adjunctive mood stabiliser vs alternative mood stabiliser</HEADING>
<P>One study used oxcarbazepine as an adjunctive augmenting medication. <LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK> examined oxcarbazepine versus carbamazepine as an adjunctive treatment to lithium. Participants had bipolar I or II disorder and suffered mania or hypomania despite lithium treatment. Changes in manic and depressive rating scales were measured.</P>
<SUBSECTION>
<HEADING LEVEL="4">3.1 PRIMARY OUTCOME MEASURE</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1.1 Number of participants who responded by 50% or more on a mood rating scale</HEADING>
<P>No data were available from the study comparing oxcarbazepine to carbamazepine as an adjunct to lithium treatment<B>
<I> </I>
</B>(<LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 SECONDARY OUTCOME MEASURE</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.2.1 Fall in mania and depression rating scales</HEADING>
<P>There was no evidence that oxcarbazepine differed from carbamazepine on mean change in  YMRS (SMD=-0.33, 95% CI -0.87 to 0.22, 1 study, n=52, P=0.2395) <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>. However, there was evidence that oxcarbazepine was superior on mean change in depressive symptoms scores on MADRS (<LINK REF="REF-Montgomery-1979" TYPE="REFERENCE">Montgomery 1979</LINK>) (SMD=- 1.12, 95% CI -1.71 to -0.53, 1 study, n=52, P=0.0002) and on mean change on the HDRS (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>) (SMD=- 0.77, 95% CI -1.35 to -0.20, 1 study, n=52, P=0.008) (<LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>) <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>, <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>.</P>
<P>
<B>3.2.2 Psychological, social and occupational functioning</B>
</P>
<P>Adjunctive oxcarbazepine treatment was superior to carbamazepine on the measure of CGI-S (<LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>). (SMD= - 1.18, 95% CI -1.77 to -0.59; z=3.90, P &lt; 0.0001) <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>. Similar results were found from this study for the outcome CGI-I, (SMD= -1.16, 95% CI -1.75 to -0.57; 1 study, n=52, P=0.0001) <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>.</P>
<P>
<B>3.2.3 Acceptability: drop out rate</B>
</P>
<P>No results could be extracted for this outcome.</P>
<P>
<B>3.2.4 Adverse effects</B>
</P>
<P>No results could be extracted for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.5 Mortality</HEADING>
<P>There was no incidence of mortality in any of the treatment groups.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Oxcarbazepine versus antipsychotics</HEADING>
<P>One study contributed to these analyses (<LINK REF="STD-Emrich-1990" TYPE="STUDY">Emrich 1990</LINK>). As mentioned before, due to quality issues we extracted tolerability data only.</P>
<SUBSECTION>
<HEADING LEVEL="5">4.2.3 Acceptability</HEADING>
<P>There was no evidence that oxcarbazepine differed from haloperidol on the outcome of physician's assessment of global tolerability (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>, <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2.4 Adverse effects</HEADING>
<P>See side effects profile by body systems (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). There was no evidence that oxcarbazepine differed from haloperidol in the occurrence of any adverse effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2.5 Mortality</HEADING>
<P>There was no incidence of mortality in either treatment groups.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Exploring heterogeneity</HEADING>
<P>The primary outcome analysis measure did not have data from sufficient studies to determine sources of heterogeneity, if any. Amongst the secondary outcome measures, there was only one efficacy analysis measure on which heterogeneity assessment could be conducted<B>
<I>, </I>
</B>(<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), comparing oxcarbazepine with valproate. There was insignificant heterogeneity between the two combined studies (<LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>; <LINK REF="STD-Kakkar-2009" TYPE="STUDY">Kakkar 2009</LINK>) (Chi<SUP>2</SUP> =0.60, df=1, P=0.44, I<SUP>2 </SUP>=0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>Such analysis was not possible because of the paucity of studies and the lack of subgroup information in the published accounts.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>As there were very few included studies we did not attempt sensitivity analyses. If such an attempt had been made, the results would be vulnerable to Type 1 errors.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-11-08 15:30:15 -0500" MODIFIED_BY="Chris Champion">
<SUMMARY_OF_RESULTS MODIFIED="2011-11-08 15:29:38 -0500" MODIFIED_BY="Chris Champion">
<P>A total of seven studies (368 participants) were eligible for inclusion in the review, four contributed to efficacy analyses.</P>
<P>Currently, the evidence for the efficacy of oxcarbazepine in the treatment of bipolar affective episodes originates from a total of four randomised controlled trials. These studies are relatively small in sample size. All the studies examine mania, though three include hypomania, mixed episodes and rapid-cycling disorder.</P>
<P>One study compares the safety and efficacy of oxcarbazepine with placebo, but only in children and adolescents (<LINK REF="STD-Wagner-2006" TYPE="STUDY">Wagner 2006</LINK>). This study did not show any difference in the treatment of mania or depressive symptoms in mixed episodes. However, it showed superior antimanic efficacy of oxcarbazepine in a subgroup analysis of children. Oxcarbazepine was tolerated less well than placebo, particularly due to its neuropsychiatric adverse effects.</P>
<P>Studies that compare oxcarbazepine with mood stabilisers (valproate, carbamazepine or lithium) in the adult population do not demonstrate a difference in anti-manic efficacy between these agents. However, there is evidence of superior efficacy of oxcarbazepine over carbamazepine as an adjunctive treatment to lithium for control of depressive symptoms during mixed episodes<B>
<I> </I>
</B>(<LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>). Nevertheless, such results should be interpreted with great caution as this analysis is based on results from a single, unreplicated study. With respect to safety, no difference was found between oxcarbazepine and other mood stabilisers.</P>
<P>One study compared oxcarbazepine with an antipsychotic, haloperidol (<LINK REF="STD-Emrich-1990" TYPE="STUDY">Emrich 1990</LINK>). Tolerability data was extracted: no difference between the groups was found.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-08-06 15:40:57 -0400" MODIFIED_BY="[Empty name]">
<P>This review demonstrates that the existing evidence supporting the use of oxcarbazepine in bipolar disorder is limited in several ways. Firstly, existing trials examine mania, mixed states, hypomania and rapid-cycling disorder. None examine depressive episodes. Secondly, there are no data comparing oxcarbazepine with placebo in adults. There are no studies comparing oxcarbazepine with active agents in children and adolescents. Data on the efficacy and safety in the elderly and safety in women of child-bearing age are not available.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>None of the trials included in this review adequately reported for all quality items. Many items were recorded as "not clear" and thus assessment of risk of bias was difficult. Most publications did not have adequate information in the published literature, however, further information was available from three of the included study authors. Studies which were published more than 20 years ago generally reported results poorly.</P>
<P>Amongst the recently published studies, sequence generation procedure was described in all but one of the studies (<LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>). The older studies did not report a method of sequence generation. Allocation concealment was not mentioned adequately in the published accounts of the newer included studies, however, trial authors described such methods to us in their correspondence, except one (<LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>). The older studies did not report method of allocation concealment either.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-11-08 15:30:15 -0500" MODIFIED_BY="Chris Champion">
<P>Attempts were made to minimise bias as much as possible. These included a comprehensive search strategy, additional handsearching of relevant literature and conference proceedings. Dedicated efforts were also made to collect additional data from authors. In addition, the study selection criteria were well defined.</P>
<P>One of the biggest limitations of the review is the small population size of individual studies.</P>
<P>
<B>1. Criteria of statistical response versus clinical response</B>
</P>
<P>The main goal of treatment of an acute bipolar episode from a clinical view is complete remission of symptoms in the patient. However, most research studies publish &gt; 50% improvement in mania rating scales as an outcome measure. Some authors have attempted to give a more relevant clinical response rate by using categorical responses of participants having a relapse after achieving remission. Such a practice is positive in this regard and should be encouraged.</P>
<P>
<B>2.</B> <B>Missing outcomes </B>
</P>
<P>Treatments for bipolar disorder should be assessed not only by psychiatric symptoms, but also by general functioning and/or Quality of Life. Such outcomes were not reported. There were no studies measuring personal, social and economic morbidity either.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="REF-Mazza-2007" TYPE="REFERENCE">Mazza 2007</LINK> provided a critical literature review of the literature on the use of oxcarbazepine in bipolar disorder. The lack of good evidence of oxcarbazepine in acute episodes of  bipolar disorder was highlighted. It was recommended that oxcarbazepine could be useful as an add-on treatment in bipolar disorder patients resistant to previous treatments or in those with difficulty tolerating adequate dosages of standard approved treatments, such as lithium and valproate. No meta-analysis was conducted. Results from open-label studies and retrospective chart reviews were considered in addition to randomised controlled trials. More recently published randomised controlled trials were not included<B>
<I> </I>
</B>(<LINK REF="STD-Juruena-2009" TYPE="STUDY">Juruena 2009</LINK>; <LINK REF="STD-Kakkar-2009" TYPE="STUDY">Kakkar 2009</LINK>; <LINK REF="STD-Suppes-2007" TYPE="STUDY">Suppes 2007</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-09-13 10:56:42 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-09-13 10:56:42 -0400" MODIFIED_BY="[Empty name]">
<P>As yet, there is insufficient evidence from randomised controlled trials on which to base recommendations for the treatment of acute episodes of bipolar disorder.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-08-23 21:53:20 -0400" MODIFIED_BY="[Empty name]">
<P>There is a need for large scale, well designed, randomised controlled trials investigating the efficacy and acceptability of oxcarbazepine in the treatment of the full range of acute affective episodes for all age groups. In particular, the role of this agent in mixed affective states and bipolar depression remains poorly investigated. Its efficacy and safety in the elderly is yet to be investigated. </P>
<P>This review highlights the need for studies to be designed well and reported with clarity. In studies of bipolar disorder, the patients&#8217; illness characteristics, their previous medication and treatment withdrawal should be reported. Methodological quality is enhanced by appropriate randomisation procedures, blinding to treatment and the full reporting of those exiting from the study early. Studies should be adequately powered. Finally, outcome measures should include factors important to patients and to clinicians, such as the length of hospitalisation and improvements in social functioning. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-12-20 07:28:30 -0500" MODIFIED_BY="Chris Champion">
<P>The authors wish to gratefully acknowledge the help of CCDAN editorial staff with the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-11-09 09:53:50 -0500" MODIFIED_BY="[Empty name]">
<P>None of the reviewers is an employee of or has shares in a pharmaceutical company. JRG currently receives research funding from UK Medical Research Council, UK Economic and Social Research Council, the National Institute for Health Research, and the Stanley Medical Research Institute. He was expert witness for Dr Reddys Laboratories and is Chief Investigator on the CEQUEL trial to which GlaxoSmithKline have contributed and supplied investigational drugs and placebo.Professor AH Young, Dr S Watson, Dr A Vasudev and Dr K Macritchie have spoken at meetings and attended conferences sponsored by various pharmaceutical companies and have participated in trials sponsored by pharmaceutical companies. Dr Karine Macritchie has worked on a project supported by an award NS-EU-166 from the Translational Medicine Research Collaboration. This consortium comprises the Universities of Aberdeen, Dundee, Edinburgh and Glasgow, the four associated NHS Health Boards (Grampian, Tayside, Lothian and Greater Glasgow and Clyde), Scottish Enterprise and Pfizer (formerly Wyeth). She has also received funding for travel, accommodation and conference expenses from Astrazeneca.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Dr A Vasudev: performed literature search, data extractions, data analysis, selection of trials, co-wrote the protocol and drafted the review<BR/>Dr KAN Macritchie: data extraction, selection of trials, co-wrote the protocol and drafted the review<BR/>Dr K Vasudev: quality assessment, contributed to drafting of the review</P>
<P>Dr S Watson: quality assessment, data extraction, contributed to drafting of the review<BR/>Prof AH Young: quality assessment, commented on the protocol and contributed to drafting of the review<BR/>Prof JR Geddes: commented on the protocol and contributed to drafting of the review</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>The search strategy has been altered (December 2010) from that which appeared in the publication of the initial protocol (2004) on the advice of CCDAN Trials Search Co-ordinator Sarah Dawson.</P>
<P>The Methods have been updated in line with the 2008 Cochrane Reviewers' Handbook, particularly as concerns 'Risk of bias' tables.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2010-06-02 08:35:00 -0400" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Emrich-1990" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Emrich 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emrich HM</AU>
<TI>Studies with oxcarbazepine in acute mania</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>83-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emrich-1990b" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Emrich 1990b" YEAR="1990">
<REFERENCE MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emrich HM</AU>
<TI>Studies with oxcarbazepine (Trileptal) in acute mania</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>83-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juruena-2009" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Juruena 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juruena MF, Ottoni GL, Machado-Vieira R, Carneiro RM, Weingarthner N, Marquardt AR, et al</AU>
<TI>Bipolar I and II disorder residual symptoms: Oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2009</YR>
<VL>33(1)</VL>
<PG>94-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakkar-2009" MODIFIED="2010-03-16 09:54:31 -0400" MODIFIED_BY="[Empty name]" NAME="Kakkar 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-03-16 09:54:31 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar AK, Rehan HS, Unni KE, Gupta NK, Chopra D, Kataria D</AU>
<TI>Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study</TI>
<SO>European Psychiatry: the Journal of the Association of European Psychiatrists</SO>
<YR>2009</YR>
<VL>24(3)</VL>
<PG>178-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mueller-1984b" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Mueller 1984b" YEAR="1984">
<REFERENCE MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Mueller AA, Stoll KD</AU>
<TI>Carbamazepine and oxcarbazepine in the treatment of manic syndromes-studies in Germany</TI>
<SO>Anticonvulsants in affective disorders</SO>
<YR>1984</YR>
<PG>139-45</PG>
<ED>Emrich HM, Okuma T, Mueller AA</ED>
<PB>Elsevier Science Publications</PB>
<CY>BV</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suppes-2007" MODIFIED="2011-10-31 09:54:41 -0400" MODIFIED_BY="[Empty name]" NAME="Suppes 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-10-31 09:54:41 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suppes T, Kelly DI, Hynan LS, Snow DE,  Sureddi S, Foster B et al</AU>
<TI>Comparison of two anticonvulsants in a randomized, single-blind treatment of hypomanic symptoms in patients with bipolar disorder</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>41(5)</VL>
<PG>397-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagner-2006" MODIFIED="2011-10-31 09:54:58 -0400" MODIFIED_BY="[Empty name]" NAME="Wagner 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-10-31 09:54:58 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K, et al</AU>
<TI>A double blind randomized placebo controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>1179-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baldessarini-2008" MODIFIED="2011-10-12 06:20:06 -0400" MODIFIED_BY="[Empty name]" NAME="Baldessarini 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-10-12 06:20:06 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baldessarini R, Henk H, Sklar A, Chang J, Leahy L</AU>
<TI>Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence</TI>
<SO>Psychiatric Services</SO>
<YR>2008</YR>
<VL>59(10)</VL>
<PG>1175-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-12-20 07:37:53 -0500" MODIFIED_BY="Chris Champion"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benedetti-2001" MODIFIED="2011-10-31 12:46:58 -0400" MODIFIED_BY="[Empty name]" NAME="Benedetti 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-10-31 12:46:58 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benedetti A, Manzi C, Bonanno C, Simonetti B, Adamovit A, Battistini G, et al</AU>
<TI>Efficacy and tolerability of oxcarbazepine in bipolar disorder: a prospective study on 24 patients [poster presentation]</TI>
<SO>European Neuropsychopharmacology [6th ECNP Regional Meeting 19-21 May, Naples, Italy]</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>Suppl 2</NO>
<PG>S39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benedetti-2004" MODIFIED="2011-10-31 10:15:25 -0400" MODIFIED_BY="[Empty name]" NAME="Benedetti 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-10-31 10:15:25 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benedetti A, Lattanzi L, Pini S, Musetti L, Dell'Osso L, Cassano GB</AU>
<TI>Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2004</YR>
<VL>79</VL>
<NO>1-3</NO>
<PG>273-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cabrera-1987" MODIFIED="2011-10-31 10:12:13 -0400" MODIFIED_BY="[Empty name]" NAME="Cabrera 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-10-31 10:12:13 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cabrera J, Albrecht J, Muller-Oerlinghausen BM</AU>
<TI>Combined prophylactic treatment of manic depressive illness with lithium and oxcarbazepine</TI>
<TO>Kombinierte rezidiv prophylaktische behandlung der manisch depressiven erkrankung mit lithium und carbamazepin oder oxcarbazepin</TO>
<SO>Nervenarzt</SO>
<YR>1987</YR>
<VL>58</VL>
<NO>4</NO>
<PG>245-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Centorrino--2003" MODIFIED="2011-10-31 10:15:56 -0400" MODIFIED_BY="[Empty name]" NAME="Centorrino  2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-31 10:15:56 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Centorrino F, Albert MJ, Berry JM, Kelleher JP, Fellman V, Line G, et al</AU>
<TI>Oxcarbazepine: clinical experience with hospitalized psychiatric patients</TI>
<SO>Bipolar Disorders</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>5</NO>
<PG>370-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Conway-2003" MODIFIED="2011-10-31 10:23:48 -0400" MODIFIED_BY="[Empty name]" NAME="Conway 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-31 10:23:48 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Conway CR, Nelson LA, McGuire JM, Bonan KE, Abraham PF, Baram VY, Chibnall J</AU>
<TI>An open-label study of adjunctive oxcarbazepine in the treatment of refractory bipolar disorder [abstract no: NR31]</TI>
<SO>American Psychiatric Association Annual Meeting [New Research Abstracts]</SO>
<YR>2003</YR>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conway-2006" MODIFIED="2010-03-16 09:41:38 -0400" MODIFIED_BY="[Empty name]" NAME="Conway 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-16 09:38:16 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conway CR, Chibnall JT, Nelson LA, McGuire JM, Abraham PF, Baram VY, et al</AU>
<TI>An open-label trial of adjunctive oxcarbazepine for bipolar disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26(1)</VL>
<PG>95-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davanzo--2004" MODIFIED="2010-03-16 09:45:40 -0400" MODIFIED_BY="[Empty name]" NAME="Davanzo  2004" YEAR="2004">
<REFERENCE MODIFIED="2010-03-16 09:40:54 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davanzo P, Nikore V, Yehya N, Stevenson L</AU>
<TI>Oxcarbazepine treatment of juvenile-onset bipolar disorder</TI>
<SO>Journal of Child &amp; Adolescent Psychopharmacology</SO>
<YR>2004</YR>
<VL>14(3)</VL>
<PG>344-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Deutschman-2003" MODIFIED="2011-10-31 10:27:22 -0400" MODIFIED_BY="[Empty name]" NAME="Deutschman 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-31 10:27:22 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Deutschman DA, Deutschman DH, Chalekian JS</AU>
<TI>Oxcarbazepine efficacy and safety in bipolar disorder: review of 249 patients [abstract no: NR246]</TI>
<SO>American Psychiatric Association Annual Meeting [New Research Abstracts]</SO>
<YR>2003</YR>
<PG>92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emrich-1983" MODIFIED="2011-10-31 10:28:35 -0400" MODIFIED_BY="[Empty name]" NAME="Emrich 1983" YEAR="1983">
<REFERENCE MODIFIED="2011-10-31 10:28:35 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emrich HM, Altmann H, Dose M, von Zerssen D</AU>
<TI>Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report</TI>
<SO>Pharmacology, Biochemistry and Behavior</SO>
<YR>1983</YR>
<VL>19</VL>
<NO>2</NO>
<PG>369-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emrich-1985" MODIFIED="2011-10-31 10:29:59 -0400" MODIFIED_BY="[Empty name]" NAME="Emrich 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-10-31 10:29:59 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emrich HM, Dose M, von Zerssen D</AU>
<TI>The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1985</YR>
<VL>8</VL>
<NO>3</NO>
<PG>243-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghaemi-2002" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Ghaemi 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghaemi SN, Ko JY, Katzow JJ</AU>
<TI>Oxcarbazepine treatment of refractory bipolar disorder: a retrospective chart review</TI>
<SO>Bipolar Disorders</SO>
<YR>2002</YR>
<VL>4</VL>
<PG>70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghaemi-2003" MODIFIED="2011-10-31 10:32:22 -0400" MODIFIED_BY="[Empty name]" NAME="Ghaemi 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-31 10:32:22 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghaemi SN, Berv DA, Klugman J, Rosenquist KJ, Hsu DJ</AU>
<TI>Oxcarbazepine treatment of bipolar disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>8</NO>
<PG>943-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greil-1985" MODIFIED="2011-10-31 10:35:27 -0400" MODIFIED_BY="[Empty name]" NAME="Greil 1985" YEAR="1983">
<REFERENCE MODIFIED="2011-10-31 10:35:27 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Greil W, Kruegger R, Rossnagl G, Schertel M, Walther A</AU>
<TI>Prophylactic treatment of affective disorders with carbamazepine and oxcarbazepine: an open clinical trial</TI>
<SO>Psychiatry: The state of the art [proceedings of VII World Congress of Psychiatry, 11-16 July 1983, Vienna, Austria]</SO>
<YR>1985</YR>
<PG>491-4</PG>
<ED>Pichot P</ED>
<PB>Plenum Press</PB>
<CY>New York; London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hummel-2002" MODIFIED="2011-10-31 10:36:04 -0400" MODIFIED_BY="[Empty name]" NAME="Hummel 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-10-31 10:36:04 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hummel B, Walden J, Stampfer R, Dittmann S, Amann B, Sterr A, Schaefer M, Frye MA, Grunze H</AU>
<TI>Acute antimanic efficacy and safety of carbamazepine in an open trial with an on-off-on design</TI>
<SO>Bipolar Disorders</SO>
<YR>2002</YR>
<VL>4</VL>
<PG>412-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalra-2006" MODIFIED="2011-10-31 10:36:21 -0400" MODIFIED_BY="[Empty name]" NAME="Kalra 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-10-31 10:36:21 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalra H, Dalal PK, Allet L, Janca A</AU>
<TI>Oxcarbazepine in a carbamazepine-intolerant patient with bipolar affective disorder: a case report</TI>
<SO>Psychiatria Danubina</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>1-2</NO>
<PG>90-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kouzavkova-1996" MODIFIED="2011-10-31 10:39:58 -0400" MODIFIED_BY="[Empty name]" NAME="Kouzavkova 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-10-31 10:39:58 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kouzavkova M, Mosolov S, Kostiukova E, Singin A</AU>
<TI>Clinico-pharmacokinetic prognosis of prophylactic efficacy of carbamazepine, oxcarbazepine and sodium valproate in affective and schizoaffective disorders [conference poster p1.081]</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>Suppl 4</NO>
<PG>S4-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lattanzi-2003" MODIFIED="2011-10-31 10:43:09 -0400" MODIFIED_BY="[Empty name]" NAME="Lattanzi 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-31 10:43:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lattanzi L, Benedetti A, Pini S, Ceraudo G, Musetti L, Cassano B</AU>
<TI>Oxcarbazepine as add on treatment in patients with bipolar manic, mixed or depressive episode</TI>
<SO>Fifth international conference of bipolar disorder</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacMillan-2006" MODIFIED="2010-03-16 09:58:57 -0400" MODIFIED_BY="[Empty name]" NAME="MacMillan 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-16 09:58:57 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacMillan CM, Korndorfer SR, Rao S, Fleisher CA, Mezzacappa E, Gonzalez-Heydrich J</AU>
<TI>A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder</TI>
<SO>Journal of Psychiatric Practice</SO>
<YR>2006</YR>
<VL>12(4)</VL>
<PG>214-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Majczenko-2007" MODIFIED="2010-03-17 05:52:42 -0400" MODIFIED_BY="[Empty name]" NAME="Majczenko 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-03-17 05:52:42 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Majczenko TG, Stewart JT</AU>
<TI>Oxcarbazepine treatment of refractory bipolar illness</TI>
<SO>Southern Medical Journal</SO>
<YR>2007</YR>
<VL>100(4)</VL>
<PG>415</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Misdrahi-2008" MODIFIED="2010-03-17 05:55:29 -0400" MODIFIED_BY="[Empty name]" NAME="Misdrahi 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-03-17 05:55:29 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Misdrahi D, Tournier M, Droulout T, Grolleau A, Titier K, Molimard M, et al</AU>
<TI>Efficiency and safety of oxcarbazepine in mood disorders: a naturalistic study exploring the interest of plasma dosages</TI>
<SO>European Psychiatry: the Journal of the Association of European Psychiatrists</SO>
<YR>2008</YR>
<VL>23(6)</VL>
<PG>409-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mosolov-2009" MODIFIED="2011-11-04 04:21:31 -0400" MODIFIED_BY="[Empty name]" NAME="Mosolov 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-04 04:21:31 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mosolov SN, Kostiukova EG, Ladyzhensky MYA</AU>
<TI>Comparative efficacy and tolerability of carbamazepine and oxcarbazepine during long therapy of patients with bipolar and schizoaffective disorders [Russian]</TI>
<SO>Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova</SO>
<YR>2009</YR>
<VL>109</VL>
<NO>10</NO>
<PG>36-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mueller-1983" MODIFIED="2011-10-31 10:54:30 -0400" MODIFIED_BY="[Empty name]" NAME="Mueller 1983" YEAR="1983">
<REFERENCE MODIFIED="2011-10-31 10:54:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mueller AA, Stoll KD, Wendt G</AU>
<TI>Oxcarbazepine in acute mania</TI>
<SO>Proceedings of the VII World Congress of Psychiatry; 1983 July 11-16; Vienna, Austria</SO>
<YR>1983</YR>
<PG>124</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mueller-1984" MODIFIED="2011-10-31 10:58:01 -0400" MODIFIED_BY="[Empty name]" NAME="Mueller 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-10-31 10:58:01 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mueller AA, Stoll KD, Kraemer G, Goncalves N</AU>
<TI>Carbamazepine, Oxcarbazepine and their metabolites. Studies in healthy volunteers, cases with epilepsy and patients with manic syndromes [abstract]</TI>
<SO>Collegium Internationale Neuro-Psychopharmacologicum:14th CINP Congress; June 19-23, 1984; Florence, Italy</SO>
<YR>1984</YR>
<PG>1073</PG>
<IDENTIFIERS MODIFIED="2011-10-12 07:35:00 -0400" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Munoz-2002" MODIFIED="2011-10-31 11:01:19 -0400" MODIFIED_BY="[Empty name]" NAME="Munoz 2002" YEAR="2003">
<REFERENCE MODIFIED="2011-10-31 11:01:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Munoz RA</AU>
<TI>Oxcarbazepine for the treatment of bipolar disorder [poster presentation, no: NR479]</TI>
<SO>American Psychiatric Association Annual Meeting [New Research Abstracts]</SO>
<YR>2002</YR>
<PG>129</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Nasr-2002" MODIFIED="2011-10-31 11:02:04 -0400" MODIFIED_BY="[Empty name]" NAME="Nasr 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-10-31 11:02:04 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nasr S</AU>
<TI>Oxcarbazepine for mood disorders</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>10</NO>
<PG>1793</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Nasr-2003" MODIFIED="2009-12-01 12:41:09 -0500" MODIFIED_BY="[Empty name]" NAME="Nasr 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nasr SJ, Casper M</AU>
<TI>Oxcarbazepine in the treatment of mood disorders</TI>
<SO>American Psychiatric Association Meeting</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NDA-application-1997" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="NDA application 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Boehm G, Burkhart G, Hershkowitz N, Katz RG, Fisher A, Fitzgerald GG et al [FDA Centre for Drug Evaluation and Research (CEDR)]</AU>
<TI>Trileptal Medical Review Part 7 [NDA 21-014, mania trial]</TI>
<SO>Drugs@FDA [http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-014_Trileptal.cfm]</SO>
<YR>1999</YR>
<PG>(accessed 31 October 2011)</PG>
<IDENTIFIERS MODIFIED="2010-03-04 05:07:38 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norton-2001" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Norton 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norton J</AU>
<TI>Oxcarbazepine in mood disorders</TI>
<SO>Hospital Pharmacy</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>12</NO>
<PG>1254-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Platt-2003" MODIFIED="2011-10-31 11:47:47 -0400" MODIFIED_BY="[Empty name]" NAME="Platt 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-31 11:47:47 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Platt DE, Munasifi FA, McKay LM</AU>
<TI>Retrospective chart review on the use of oxcarbazepine in patients with bipolar disorder [poster presentation, no: NR519 ]</TI>
<SO>American Psychiatric Association Annual Meeting [New Research Abstracts]</SO>
<YR>2003</YR>
<PG>194</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pratoomsri-2005" MODIFIED="2011-10-31 11:48:06 -0400" MODIFIED_BY="[Empty name]" NAME="Pratoomsri 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-10-31 11:48:06 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pratoomsri W, Yatham LN, Sohn CH, Solomons K, Lam RW</AU>
<TI>Oxcarbazepine add-on in the treatment of refractory bipolar disorder</TI>
<SO>Bipolar Disorders</SO>
<YR>2005 </YR>
<VL>7</VL>
<NO>Suppl 5</NO>
<PG>37-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raja-2003" MODIFIED="2011-10-31 11:48:18 -0400" MODIFIED_BY="[Empty name]" NAME="Raja 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-31 11:48:18 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raja M, Azzoni A</AU>
<TI>Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>4</NO>
<PG>409-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reinstein-2003" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Reinstein 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reinstein MJ, Sonnenberg JG, Hedberg TG, Jones LE, Reyngold P</AU>
<TI>Oxcarbazepine versus divalproex sodium for the continuing treatment of mania</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>10</NO>
<PG>671-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosa-2009" MODIFIED="2011-10-31 11:51:16 -0400" MODIFIED_BY="[Empty name]" NAME="Rosa 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-10-31 11:51:16 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosa AR, Cruz N, Comes M, Vieta E</AU>
<TI>Impulsivity in bipolar disorder: a randomized clinical trial of adjunctive oxcarbazepine [poster presentation, p.3.16]</TI>
<SO>European Neuropsychopharmacology [papers of the 2009 ECNP Workshop on Neuropsychopharmacology for Young Scientists in Europe; Nice, France]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>Suppl 1</NO>
<PG>S75-S76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-10-12 07:34:48 -0400" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salpekar-2006" MODIFIED="2011-10-31 11:51:53 -0400" MODIFIED_BY="[Empty name]" NAME="Salpekar 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-10-31 11:51:53 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salpekar JA, Conry JA, Doss W, Cushner-Weinstein S, Pearl PL, Weinstein SL, et al</AU>
<TI>Clinical experience with anticonvulsant medication in pediatric epilepsy and comorbid bipolar spectrum disorder</TI>
<SO>Epilepsy and Behavior</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>2</NO>
<PG>327-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaffer-2003" MODIFIED="2011-10-31 11:52:03 -0400" MODIFIED_BY="[Empty name]" NAME="Schaffer 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-31 11:52:03 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Schaffer CB, Schaffer LC</AU>
<TI>Oxcarbazepine for refractory bipolar disorder</TI>
<SO>Fifth international conference on bipolar disorder</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tavormina-2000" MODIFIED="2011-10-31 11:56:25 -0400" MODIFIED_BY="[Empty name]" NAME="Tavormina 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-10-31 11:56:25 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tavormina G</AU>
<TI>Oxcarbazepine as a mood regulator: its efficacy, safety and tolerability versus carbamazepine [poster presentation, no: p01.70]</TI>
<SO>European Psychiatry [abstracts of the Congress of the Association of European Psychiatrists; Prague, Czech Republic]</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>Suppl 2</NO>
<PG>s339</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teitelbaum-2001" MODIFIED="2011-10-31 11:57:19 -0400" MODIFIED_BY="[Empty name]" NAME="Teitelbaum 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-10-31 11:57:19 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teitelbaum M</AU>
<TI>Oxcarbazepine in bipolar disorder</TI>
<SO>Journal of the American Academy of Child and Adolescent Psychiatry</SO>
<YR>2001</YR>
<VL>40</VL>
<NO>9</NO>
<PG>993-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Velikonja-1984" MODIFIED="2011-10-31 11:58:34 -0400" MODIFIED_BY="[Empty name]" NAME="Velikonja 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-10-31 11:58:34 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Velikonja M, Heinrich K</AU>
<TI>Effect of oxcarbazepine on affective and schizoaffective symptoms: A Preliminary Report</TI>
<SO>Anticonvulsants in affective disorders (International Congress Series; no 626)</SO>
<YR>1984</YR>
<PG>208-10</PG>
<ED>Emrich HM, Okuma T, Muller AA</ED>
<PB>Excerpta Medica</PB>
<CY>Amsterdam; Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vieta-2008" MODIFIED="2011-10-12 06:29:21 -0400" MODIFIED_BY="[Empty name]" NAME="Vieta 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-03-17 09:49:57 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vieta E, Cruz N, Garcia-Campayo J, de Arce R, Manuel Crespo J, Valles V, Perez-Blanco J, Roca E, Manuel Olivares J, Morinigo A, Fernandez-Villamor R, Comes M</AU>
<TI>A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>11(4)</VL>
<PG>445-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-10-12 06:29:21 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-10-12 06:29:21 -0400" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00154323"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wildgrube-1990" MODIFIED="2009-12-01 13:30:18 -0500" MODIFIED_BY="[Empty name]" NAME="Wildgrube 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wildgrube C</AU>
<TI>Case studies on prophylactic long term effects of oxcarbazepine in recurrent affective disorders</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>89-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2011-10-12 07:43:21 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-IRCT201012055280N2" MODIFIED="2011-10-12 07:43:21 -0400" MODIFIED_BY="[Empty name]" NAME="IRCT201012055280N2" YEAR="2011">
<REFERENCE MODIFIED="2011-10-12 07:34:18 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Talaei A, Soltanifar A</AU>
<TI>Therapeutic Efficacy of Oxcarbazepine and Sodium Valproate in Acute Mania [IRCT201012055280N2]</TI>
<SO>Iranian Clinical Trials Registry [http://www.irct.ir/index.php]</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abrams-2005" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Abrams 2005" TYPE="JOURNAL_ARTICLE">
<AU>Abrams KR, Gillies CL, Lambert PC</AU>
<TI>Meta-analysis of heterogeneously reported trials assessing change from baseline</TI>
<SO>Statistics in Medicine</SO>
<YR>2005</YR>
<VL>24</VL>
<PG>3823-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Akiskal-2000" MODIFIED="2010-12-15 03:48:57 -0500" MODIFIED_BY="Chris Champion" NAME="Akiskal 2000" TYPE="JOURNAL_ARTICLE">
<AU>Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R</AU>
<TI>Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2000</YR>
<VL>59</VL>
<NO>Suppl 1</NO>
<PG>5-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman D, Bland M</AU>
<TI>Detecting skewness from summary information</TI>
<SO>British Medical Journal</SO>
<YR>1996</YR>
<VL>313</VL>
<NO>7066</NO>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-2000" MODIFIED="2011-01-08 14:18:48 -0500" MODIFIED_BY="[Empty name]" NAME="APA 2000" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistics Manual of mental disorders (DSM-IV)-TR (Text Revision)</SO>
<YR>2000</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bech-1979" MODIFIED="2011-11-04 04:14:24 -0400" MODIFIED_BY="[Empty name]" NAME="Bech 1979" TYPE="JOURNAL_ARTICLE">
<AU>Bech P, Bolwig TG, Kramp P and Rafaelsen OJ</AU>
<TI>The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1979</YR>
<VL>59</VL>
<NO>4</NO>
<PG>420-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beydoun-2002" NAME="Beydoun 2002" TYPE="JOURNAL_ARTICLE">
<AU>Beydoun A, Kutluay E</AU>
<TI>Oxcarbazepine</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>1</NO>
<PG>59-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bowden-1996" NAME="Bowden 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bowden CL</AU>
<TI>Role of newer medications for bipolar disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>2 Suppl 1</NO>
<PG>48-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davanzo-2004" MODIFIED="2011-11-04 04:22:20 -0400" MODIFIED_BY="[Empty name]" NAME="Davanzo 2004" TYPE="JOURNAL_ARTICLE">
<AU>Davanzo P, Nikore V, Yehya N, Stevenson L</AU>
<TI>Oxcarbazepine treatment of juvenile-onset bipolar disorder</TI>
<SO>Journal of Child and Adolescent Psychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>3</NO>
<PG>344-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dietrich-2001" NAME="Dietrich 2001" TYPE="JOURNAL_ARTICLE">
<AU>Dietrich DE, Kropp S, Emrich HM</AU>
<TI>Oxcarbazepine in affective and schizoaffective disorders</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>6</NO>
<PG>242-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dong-2005" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Dong 2005" TYPE="JOURNAL_ARTICLE">
<AU>Dong X, Ilo E, Leppik IE, White J, Rarick J</AU>
<TI>Hyponatremia from oxcarbazepine and carbamazepine</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>65</VL>
<PG>1976-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Follmann-1992" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Follmann 1992" TYPE="JOURNAL_ARTICLE">
<AU>Follmann D, Elliott P, Suh I, Cutler J</AU>
<TI>Variance imputation for overviews of clinical trials with continuous response</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1992</YR>
<VL>45</VL>
<PG>769-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Franks-2008" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Franks 2008" TYPE="JOURNAL_ARTICLE">
<AU>Franks MA, Macritchie KA, Mahmood T, Young AH</AU>
<TI>Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>4</NO>
<PG>452-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2002" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Furukawa 2002" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Guyatt GH, Griffith LE</AU>
<TI>Can we individualize the 'number needed to treat&#8217;? An empirical study of summary effect measures in meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>72-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gelder-2003" NAME="Gelder 2003" TYPE="BOOK">
<AU>Gelder MG, Lopez Ibor JJ, Andreasen NC</AU>
<SO>New Oxford Textbook of Psychiatry</SO>
<YR>2003</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodwin-1994" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Goodwin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Goodwin GM</AU>
<TI>Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>164</VL>
<NO>2</NO>
<PG>149-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodwin-2009" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Goodwin 2009" TYPE="JOURNAL_ARTICLE">
<AU>Goodwin GM</AU>
<TI>Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>4</NO>
<PG>346-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2010-12-15 03:49:28 -0500" MODIFIED_BY="Chris Champion" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>ECDEU Assessment Manual for Psychopharmacology</SO>
<YR>1976</YR>
<EN>(Revised Edition)</EN>
<PB>National Institute of Mental Health.</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" MODIFIED="2011-10-31 12:00:15 -0400" MODIFIED_BY="[Empty name]" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>A rating scale for depression</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56&#8211;62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hellewell-2002" MODIFIED="2010-03-16 09:48:51 -0400" MODIFIED_BY="[Empty name]" NAME="Hellewell 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hellewell JS</AU>
<TI>Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2002</YR>
<VL>72 Suppl 1</VL>
<PG>S23-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-12-01 13:28:29 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]</TI>
<SO>The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Isojarvi-1994" NAME="Isojarvi 1994" TYPE="JOURNAL_ARTICLE">
<AU>Isojarvi V, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV</AU>
<TI>Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine</TI>
<SO>Epilepsia</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>6</NO>
<PG>1217-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keck-2000" NAME="Keck 2000" TYPE="JOURNAL_ARTICLE">
<AU>Keck PE Jr, McElroy SL, Strakowski SM, Soutullo CA</AU>
<TI>Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>Suppl 4</NO>
<PG>33-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Landgraf-1999" MODIFIED="2010-06-14 05:54:50 -0400" MODIFIED_BY="[Empty name]" NAME="Landgraf 1999" TYPE="BOOK">
<AU>Landgraf JM, Abetz L, Ware Je</AU>
<TI>The Child Heath Questionnaire(CHQ) : A user's manual</TI>
<SO>The Child Heath Questionnaire(CHQ) : A user's manual</SO>
<YR>1999</YR>
<EN>2nd</EN>
<PB>Health Act</PB>
<CY>Boston</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Macritchie-2009" MODIFIED="2011-10-12 02:44:24 -0400" MODIFIED_BY="Chris Champion" NAME="Macritchie 2009" TYPE="COCHRANE_REVIEW">
<AU>Macritchie K, Geddes J, Scott J, Haslam DR, Silva de Lima M, Goodwin G</AU>
<TI>Valproate for acute mood episodes in bipolar disorder</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-10-12 02:44:17 -0400" MODIFIED_BY="Chris Champion">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004052"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mazza-2007" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Mazza 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mazza M, Nicola MD, Martinotti G, Taranto C, Pozzi G, Conte G, Janiri L, Bria P, Mazza S</AU>
<TI>Oxcarbazepine in bipolar disorder: a critical review of the literature</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>5</NO>
<PG>649-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moncrieff-1997" MODIFIED="2011-10-12 07:45:07 -0400" MODIFIED_BY="[Empty name]" NAME="Moncrieff 1997" TYPE="JOURNAL_ARTICLE">
<AU>Moncrieff J</AU>
<TI>Lithium: evidence reconsidered</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>171</VL>
<PG>113-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montgomery-1979" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Montgomery 1979" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Asberg M</AU>
<TI>A new depression scale designed to be sensitive to change</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>134</VL>
<PG>382&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Muller-1984" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Muller 1984" TYPE="BOOK_SECTION">
<AU>Muller AA, Stoll KD</AU>
<TI>Carbamazepine and oxcarbazepine in the treatment of manic syndromes: studies in Germany</TI>
<SO>Anticonvulsants in affective disorders</SO>
<YR>1984</YR>
<PG>139-47</PG>
<ED>Emrich HM, Okuma T, Muller AA</ED>
<PB>Elsevier Science Ltd</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oxman-1995" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Oxman 1995" TYPE="BOOK_SECTION">
<AU>Oxman A</AU>
<TI>Preparing and maintaining systematic reviews</TI>
<SO>Cochrane Collaboration Handbook</SO>
<YR>1995</YR>
<VL>section VI, updated 14th July</VL>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PDR-2001" NAME="PDR 2001" TYPE="BOOK">
<AU>Medical Economics Co</AU>
<SO>Physicians' Desk Reference</SO>
<YR>2001</YR>
<EN>55th</EN>
<PB>Medical Economics Co</PB>
<CY>Montvale, NJ</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poznaski-1984" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Poznaski 1984" TYPE="JOURNAL_ARTICLE">
<AU>Poznaski EO, Miller E, Salguero C, Kelsh RC</AU>
<TI>Preliminary studies of the reliability and validity of the children's depression rating scale</TI>
<SO>Journal of the American Academy of Child Psychiatry</SO>
<YR>1984</YR>
<VL>23</VL>
<PG>191-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schatzberg-2004" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Schatzberg 2004" TYPE="BOOK">
<AU>Schatzberg AF, Nemeroff CB</AU>
<SO>The American Psychiatric Publishing Textbook of Psychopharmacology</SO>
<YR>2004</YR>
<PB>American Psychiatric Publishing Inc</PB>
<CY>Arlington, VA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spearing-1997" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Spearing 1997" TYPE="JOURNAL_ARTICLE">
<AU>Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W</AU>
<TI>Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP</TI>
<SO>Psychiatry Research</SO>
<YR>1997</YR>
<VL>73</VL>
<PG>159-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stahl-2000" NAME="Stahl 2000" TYPE="BOOK">
<AU>Stahl SM</AU>
<SO>Essential psychopharmacology of depression and bipolar disorder</SO>
<YR>2000</YR>
<PB>Cambridge University Press</PB>
<CY>Cambridge</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suppes-1991" MODIFIED="2011-10-12 07:44:10 -0400" MODIFIED_BY="[Empty name]" NAME="Suppes 1991" TYPE="JOURNAL_ARTICLE">
<AU>Suppes T, Baldessarini RJ, Faedda GL, Tohen M</AU>
<TI>Risk of recurrence following discontinuation of lithium treatment in bipolar disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1991</YR>
<VL>48</VL>
<NO>12</NO>
<PG>1082-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vasudev-2009" MODIFIED="2011-10-12 02:44:24 -0400" MODIFIED_BY="Chris Champion" NAME="Vasudev 2009" TYPE="COCHRANE_REVIEW">
<AU>Vasudev A, Macritchie K, Rao SNK, Geddes J, Young AH</AU>
<TI>Tiagabine in the treatment of acute affective episodes in bipolar disorder</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-10-12 02:44:17 -0400" MODIFIED_BY="Chris Champion">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004694.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vasudev-2009a" MODIFIED="2011-10-12 02:44:24 -0400" MODIFIED_BY="Chris Champion" NAME="Vasudev 2009a" TYPE="COCHRANE_REVIEW">
<AU>Vasudev K, Macritchie K, Geddes J, Watson S, Young AH</AU>
<TI>Topiramate for acute affective episodes in bipolar disorder</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-10-12 02:44:17 -0400" MODIFIED_BY="Chris Champion">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003384.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weisler-2006" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NAME="Weisler 2006" TYPE="JOURNAL_ARTICLE">
<AU>Weisler, RH, Hirschfeld, R, Cutler, AJ, Gazda, T, Ketter, TA, Keck, PE, et al</AU>
<TI>Extended-release carbamazepine capsules as monotherapy in bipolar disorder - Pooled results from two randomised, double-blind, placebo-controlled trials</TI>
<SO>CNS Drugs</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>219-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1992" NAME="WHO 1992" TYPE="BOOK">
<AU>World Health Organisation</AU>
<SO>The ICD-10 Classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines</SO>
<YR>1992</YR>
<PB>World Health Organisation</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-1978" MODIFIED="2010-05-25 09:57:26 -0400" MODIFIED_BY="[Empty name]" NAME="Young 1978" TYPE="JOURNAL_ARTICLE">
<AU>Young RC, Biggs JT, Ziegler VE, Meyer DA</AU>
<TI>A rating scale for mania: reliability, validity and sensitivity</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1978</YR>
<VL>133</VL>
<PG>429-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-2006" MODIFIED="2011-01-20 03:58:31 -0500" MODIFIED_BY="Chris Champion" NAME="Young 2006" TYPE="COCHRANE_REVIEW">
<AU>Young AH, Geddes JR, Macritchie K, Rao SN, Watson S, Vasudev A</AU>
<TI>Tiagabine in the treatment of acute affective episodes in bipolar disorder: efficacy and acceptability</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-01-20 03:58:31 -0500" MODIFIED_BY="Chris Champion">
<IDENTIFIER MODIFIED="2011-01-20 03:58:31 -0500" MODIFIED_BY="Chris Champion" TYPE="DOI" VALUE="10.1002/14651858.CD004694.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-11-08 15:26:07 -0500" MODIFIED_BY="Chris Champion">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-11-08 15:23:34 -0500" MODIFIED_BY="Chris Champion" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-11-08 15:21:55 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Emrich-1990">
<CHAR_METHODS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Allocation: multicentric randomised trial</P>
<P>Blinding: double blind</P>
<P>Duration:15 days</P>
<P>Setting: multicentric</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 15:21:52 -0500" MODIFIED_BY="Chris Champion">
<P>Thirty-eight participants with acute manic syndromes according to DSM III were randomised equally to oxcarbazepine or haloperidol.</P>
<P>Age range: not specified</P>
<P>Exclusion criteria: not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 15:21:55 -0500" MODIFIED_BY="Chris Champion">
<P>1. Oxcarbazepine, 19 participants, 900 mg/day/patient during first two days with a possibility of increasing the dose later. Maximum dose used of oxcarbazepine was 4500 mg.<BR/>2. Haloperidol, 19 participants, started at a dose of 15 mg/day/patient for the first two days with the possibility of increasing the dose further later. Maximum dose used was 135 mg/day.</P>
<P>Other medications, if used, not described.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Fall in 11 item BRMAS mania rating scores from baseline to day 15.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Study sponsored by pharmaceutical company.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 15:21:58 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Emrich-1990b">
<CHAR_METHODS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised trial</P>
<P>Blinding: double blind</P>
<P>Duration: 15 days</P>
<P>Setting: multicentric</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 15:21:56 -0500" MODIFIED_BY="Chris Champion">
<P>Fifty-two participants with acute mania according to DSM III were randomised to receive oxcarbazepine or lithium.</P>
<P>Age range: not specified.</P>
<P>Exclusion criteria: not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>1. Oxcarbazepine 900 mg/day/patient during first two days with a possibility of increasing the dose later. Maximum dose used was 3600 mg.<BR/>2. Lithium three tablets (dose not known) for the first two days with the possibility of increasing the dose further later. Maximum dose was 2700 mg.</P>
<P>Other medications, if used, not described.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="Chris Champion">
<P>Fall in BRMAS mania rating scores from baseline to day 15 (Bech et al<I>.</I> 1979).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-08 15:21:58 -0500" MODIFIED_BY="Chris Champion">
<P>Twenty-eight participants randomised to receive oxcarbazepine and 24 randomised to receive lithium.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 15:13:08 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Juruena-2009">
<CHAR_METHODS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Allocation: oxcarbazepine compared to carbamazepine as an add-on to lithium</P>
<P>Blinding: double blind</P>
<P>Duration: 8 weeks</P>
<P>Setting: Outpatients, single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Fifty-two participants with diagnosis of bipolar disorder diagnosed using Research Diagnostic Criteria (SADS-L) currently manic or hypomanic not completely treated with lithium monotherapy randomised equally to two treatment arms.</P>
<P>Age range: not specified in published literature, clarification from author confirmed only working age adults were included (aged 18 to 60 yrs of age).</P>
<P>Inclusion criteria: not using other psychoactive drugs at least two weeks prior to inclusion, serum sodium levels &gt;=135mmol/L.</P>
<P>Exclusion criteria: Not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 15:13:08 -0500" MODIFIED_BY="Chris Champion">
<P>1. Oxcarbazepine: starting dose 300 mg/day, maintained for first three days and then uptitrated every two days by 300 mg/day to maximum of 600 to 1200 mg/day.</P>
<P>2. Carbamazepine: starting dose 200mg/day, maintained for first three days and then uptitrated every two days by 200 mg/day to maximum of 600 to 1200 mg/day.</P>
<P>Lithium allowed on open-label basis to both arms.</P>
<P>Lorazepam up to 5mg/day for management of anxiety or insomnia allowed in both arms.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Fall in YMRS, HDRS, MADRS, CGI-S, CGI-C. Data collected at 0 weeks, 2 weeks, 4 weeks and 8 weeks post- randomisation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Sponsored by pharmaceutical company.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 15:22:17 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Kakkar-2009">
<CHAR_METHODS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Allocation: oxcarbazepine compared to divalproex sodium</P>
<P>Blinding: double blind</P>
<P>Duration: 12 weeks</P>
<P>Setting: in-patient for at least first week followed by outpatient. Single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 15:22:12 -0500" MODIFIED_BY="Chris Champion">
<P>Sixty adult participants with diagnosis of bipolar disorder as per DMS-IV criteria, currently manic, mixed affective or rapid-cycling states.</P>
<P>Age range:18 to 50 yrs.</P>
<P>Inclusion criteria: baseline YMRS &gt; 20.</P>
<P>Exclusion criteria: participants with hypomania, mixed affective states and rapid-cycling states. Serious and unstable medical illness, substance dependence in the past 30 days(except nicotine or coffee); history of intolerance to oxcarbazepine or divalproex; treatment with lithium, anticonvulsant or antipsychotic within 24 hours of randomisation, serious suicidal risk, pregnant or lactating women.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="Chris Champion">
<P>1. Thirty participants received oxcarbazepine starting dose of 300 mg/day increasing to maximum of 2400 mg/day. Dose could be reduced if intolerable side effects.</P>
<P>2. Thirty participants received divalproex sodium starting dose of 750 mg/day up to maximum of 2000mg/day. Dose could be reduced if intolerable side effects.</P>
<P>Lorazepam up to 2mg/day for control of agitation, irritation, restlessness, insomnia and hostility. Not permitted 8 hours before behavioural assessment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Fall in YMRS, percentage achieving remission, percentage having relapse after achieving remission, adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-08 15:22:17 -0500" MODIFIED_BY="Chris Champion">
<P>Method of drug administration unclear: whether this was in participants who were drug-naive or if this was an add-on therapy. No obvious run-in period of trial medications.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 15:22:40 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Mueller-1984b">
<CHAR_METHODS MODIFIED="2011-10-13 07:27:16 -0400" MODIFIED_BY="[Empty name]">
<P>Allocation: Random </P>
<P>Blinding: Not known</P>
<P>Duration: 2 weeks</P>
<P>Setting: Single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 15:22:37 -0500" MODIFIED_BY="Chris Champion">
<P>20 participants with mania.</P>
<P>Diagnostic criteria: not known.</P>
<P>Age range: not known.</P>
<P>Inclusion criteria: not known.</P>
<P>Exclusion criteria: not known.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 15:22:40 -0500" MODIFIED_BY="Chris Champion">
<P>1. Ten participants randomised to oxcarbazepine, dose range 900 to 1200 mg/day.</P>
<P>2. Ten participants randomised to haloperidol, dose range 15 to 20 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Changes in BRMAS scores over two weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>No information available regarding concomitant medications, wash out of previous medications.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 15:22:41 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Suppes-2007">
<CHAR_METHODS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Allocation: random allocation</P>
<P>Blinding: single blind (rater)</P>
<P>Duration: eight weeks</P>
<P>Setting: single centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 15:22:41 -0500" MODIFIED_BY="Chris Champion">
<P>Thirty adult participants with hypomania using DSM-IV criteria.</P>
<P>Age range: 18-65 years.</P>
<P>Inclusion criteria: currently hypomanic as per YMRS &gt; 12. No medication or a stable medication regimen for at least one month prior to study entry. Serum sodium levels between 134 and 146 meq/L.</P>
<P>Exclusion criteria: substance abuse/dependence within past one month, pregnant or lactating, history of hypersensitivity to oxcarbazepine or carbamazepine, chronic infectious disease, severe liver disease, hyponatremia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>1. Probably 15 participants randomised to oxcarbazepine (initiated at 300 mg/day and increased up to 2400 mg/day). No mention of how dose was titrated.</P>
<P>2. Probably 15 participants randomised to divalproex (initiated at 500 mg/day and increased to achieve minimum serum levels of 50 mg/ml).</P>
<P>Above medications offered as either add-on or monotherapy.</P>
<P>Additional lorazepam up to 10 mg/day allowed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Fall in YMRS, IDS-C, CGI-C, adverse events only if they were considered to have functional disability.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>No wash out period, Concomitant medications not changed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 15:23:28 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Wagner-2006">
<CHAR_METHODS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="Chris Champion">
<P>Allocation: randomised controlled trial</P>
<P>Blinding: double blind</P>
<P>Duration: 7 weeks</P>
<P>Setting: outpatients, multicentre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 15:23:28 -0500" MODIFIED_BY="Chris Champion">
<P>One hundred and sixteen children and adolescent drug-naive participants fulfilling DSM-IV and K-SADS-PL criteria of mania or mixed affective states . Wash out of previous psychotropic before randomisation.</P>
<P>Age range:seven to 18 years of age.</P>
<P>Inclusion criteria: bipolar I disorder currently manic or mixed, YMRS &gt; 20. Comorbid ADHD allowed. Free of psychotropic medication except stimulants and diphenhydramine.</P>
<P>Exclusion criteria: current diagnosis of schizophrenia, delirium, anorexia nervosa, autism, bulimia, substance induced mood disorder, need for in-patient or partial psychiatric hospitalisation, participants having extreme manic episode, IQ below 70, history of psychogenic polydipsia, risk of suicide or homicide, pregnant or lactating, sodium levels &lt; 135 meq/L, current treatment with oxcarbazepine or previous failure to respond to oxcarbazepine, participants taking or planning to take an investigational drug within one month of entering study, those receiving antimanic medication that could not be tapered, known hypersensitivity to trial medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>1. Fifty-nine participants randomised to oxcarbazepine (flexible dose of 900 to 2400 mg/day).<BR/>2. Fifty-seven participants randomised to placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Changes in YMRS, Childrens depression rating scale, Clinical Global Impression scale, Child Health Questionnaire (global health and global behaviour).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-02 10:37:47 -0400" MODIFIED_BY="[Empty name]">
<P>Study sponsored by pharmaceutical company.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-11-08 15:25:41 -0500" MODIFIED_BY="Chris Champion" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baldessarini-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Non-randomised study assessing prescription pattern and non-adherence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:23:44 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Benedetti-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:23:44 -0500" MODIFIED_BY="Chris Champion">
<P>
<BR/>Open-label study of adjunctive oxcarbazepine in 24 bipolar participants followed up for 48 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:23:48 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Benedetti-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:23:48 -0500" MODIFIED_BY="Chris Champion">
<P>An open-label add-on trial, with no control group in 18 participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:23:50 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Cabrera-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:23:50 -0500" MODIFIED_BY="Chris Champion">
<P>Combined open-label prophylactic treatment with oxcarbazepine in three participants with bipolar disorder</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 09:39:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Centorrino--2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 09:39:18 -0400" MODIFIED_BY="[Empty name]">
<P>Case note review. No active intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:24:01 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Conway-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:24:01 -0500" MODIFIED_BY="Chris Champion">
<P>Open-label study of adjunctive oxcarbazepine in 14 bipolar I participants followed prospectively for 24 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Conway-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Open-label study of adjunctive oxcarbazepine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davanzo--2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Case report of oxcarbazepine in two adolescents with bipolar disorder</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:24:08 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Deutschman-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:24:08 -0500" MODIFIED_BY="Chris Champion">
<P>Retrospective chart review of 249 patients with Bipolar disorder I, II or NOS treated in an open-label, naturalistic design treated with oxcarbazepine for 42 to 484 days. It was not possible to find out whether the participants were prescribed monotherapy or add-on oxcarbazepine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:24:11 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Emrich-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:24:11 -0500" MODIFIED_BY="Chris Champion">
<P>Six participants with maniform psychoses treated with oxcarbazepine in an ABA design compared to placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:24:15 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Emrich-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:24:15 -0500" MODIFIED_BY="Chris Champion">
<P>Acute antimanic effects of oxcarbazepine in seven participants with manic syndromes compared to those of valproate. Double blind placebo controlled ABA design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:24:19 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Ghaemi-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:24:19 -0500" MODIFIED_BY="Chris Champion">
<P>Retrospective chart review of usage of oxcarbazepine as either monotherapy or add-on mood stabiliser in 13 participants suffering from refractory bipolar disorder</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 09:45:16 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghaemi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 09:45:16 -0400" MODIFIED_BY="[Empty name]">
<P>Chart review of 42 outpatients with bipolar disorder</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:24:23 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Greil-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:24:23 -0500" MODIFIED_BY="Chris Champion">
<P>Open clinical trial of oxcarbazepine in bipolar and schizoaffective psychoses conducted in 13 participants treated for two to 11 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:24:26 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Hummel-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:24:26 -0500" MODIFIED_BY="Chris Champion">
<P>Open-label trial with on-off-on design conducted on 12 manic participants (bipolar I and II) subjected to monotherapy with oxcarbazepine for 35 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-07 07:55:44 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalra-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-07 07:55:44 -0400" MODIFIED_BY="[Empty name]">
<P>Case report of one patient who was intolerant of carbamazepine was put on oxcarbazepine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:24:29 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Kouzavkova-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:24:29 -0500" MODIFIED_BY="Chris Champion">
<P>Open-label (non randomised) administration of carbamazepine oxcarbazepine and sodium valproate in 76 participants suffering from affective and schizoaffective disorders</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:24:35 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Lattanzi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:24:35 -0500" MODIFIED_BY="Chris Champion">
<P>Add-on treatment of bipolar participants with oxcarbazepine. No further details available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 09:59:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MacMillan-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 09:59:29 -0400" MODIFIED_BY="[Empty name]">
<P>Case note review of 11 patients on oxcarbazepine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-17 05:53:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Majczenko-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-17 05:53:19 -0400" MODIFIED_BY="[Empty name]">
<P>Case report of one bipolar patient treated with oxcarbazepine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-17 05:56:30 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Misdrahi-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-17 05:56:30 -0400" MODIFIED_BY="[Empty name]">
<P>Case note review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-01-08 17:15:12 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mosolov-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-01-08 17:15:12 -0500" MODIFIED_BY="[Empty name]">
<P>Usage of oxcarbazepine in maintenance treatment of bipolar disorder</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mueller-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Pilot trial of 48 anti-manic treatments with open-label oxcarbazepine. No further details available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mueller-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Results of five "trials" (patients) in manic syndromes, with carbamazepine and oxcarbazepine were presented. Details not known</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:25:01 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Munoz-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:25:01 -0500" MODIFIED_BY="Chris Champion">
<P>Open-label study of adjunctive oxcarbazepine in 30 bipolar I and II participants followed for 12 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nasr-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Case notes of four patients treated with oxcarbazepine as add-on or monotherapy in Bipolar II disorder</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nasr-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Retrospective chart review of oxcarbazepine in 88 patients with mood disorders (unipolar depression, bipolar disorder and other diagnoses) prescribed for a minimum of four weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NDA-application-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Double blind placebo controlled study of oxcarbazepine in acute mania conducted by pharmaceutical manufacturer. Study report submitted to FDA as part of NDA. Trial excluded as study failed to complete enrolment for the study. Also NDA application mentions that oxcarbazepine was given for only two days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:25:17 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Norton-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:25:17 -0500" MODIFIED_BY="Chris Champion">
<P>Prospective open-label study of oxcarbazepine in three participants suffering from bipolar or schizoaffective disorder</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Platt-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Retrospective chart review of usage of oxcarbazepine as add-on or monotherapy in 146 patients with bipolar disorder</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-17 06:05:56 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pratoomsri-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-17 06:05:56 -0400" MODIFIED_BY="[Empty name]">
<P>Retrospective case note review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-17 06:07:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raja-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-17 06:07:48 -0400" MODIFIED_BY="[Empty name]">
<P>Retrospective case note review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:25:30 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Reinstein-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:25:30 -0500" MODIFIED_BY="Chris Champion">
<P>Open-label study of single (rater) blind addition of oxcarbazepine to participants currently being administered valproate for continuing treatment of mania. No wash out of valproate conducted</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:25:34 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Rosa-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:25:34 -0500" MODIFIED_BY="Chris Champion">
<P>Adjunctive treatment of oxcarbazepine for treatment of impulsivity in long term treatment of bipolar disorder in participants who are in remission</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-17 06:09:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salpekar-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-17 06:09:47 -0400" MODIFIED_BY="[Empty name]">
<P>Retrospective chart review in 38 children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:25:36 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Schaffer-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:25:36 -0500" MODIFIED_BY="Chris Champion">
<P>Open-label study with usage of oxcarbazepine as an add-on agent in 28 participants of refractory bipolar disorder</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:25:38 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Tavormina-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:25:38 -0500" MODIFIED_BY="Chris Champion">
<P>Open-label study on 13 participants with bipolar disorder who were not tolerating carbamazepine, were administered oxcarbazepine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teitelbaum-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Case report of oxcarbazepine usage in a six year old child</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 15:25:41 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-Velikonja-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 15:25:41 -0500" MODIFIED_BY="Chris Champion">
<P>Open study (non-randomised) on 10 participants with manic and schizoaffective psychosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vieta-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised placebo controlled study for long term (prophylaxis) of oxcarbazepine as adjunctive treatment to lithium</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wildgrube-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Open-label long-term oxcarbazepine study in recurrent affective disorders</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-11-08 15:26:07 -0500" MODIFIED_BY="Chris Champion" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2011-11-08 15:26:07 -0500" MODIFIED_BY="Chris Champion" STUDY_ID="STD-IRCT201012055280N2">
<CHAR_STUDY_NAME MODIFIED="2011-10-15 06:13:43 -0400" MODIFIED_BY="[Empty name]">
<P>Therapeutic Efficacy of Oxcarbazepine and Sodium Valproate in Acute Mania</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised, parallel group, double blind study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 15:26:03 -0500" MODIFIED_BY="Chris Champion">
<P>Inclusion criteria: for eligibility in the study participants had to be 18 to 60 years of age and with DSM- IV- TR axis I diagnosis of BMD-I in acute manic episode. Exclusion criteria included a primary diagnosis of schizophrenia, delirium, anorexia nervosa, bulimia, autism, substance abuse, mental retardation and ADHD in recent three months. Other exclusion criteria were a history of epilepsy, a history of psychogenic polydipsia, a history of symptomatic hyponatremia and participants who were taking other antimanic medications during the study prior or within one week before it. Participants were required to be free of psychotropic drugs with exceptions of diphenhydramine or lorazepam for control of agitation and aggression. Risperidone 2-4 mg/day was prescribed for all of participants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 15:26:07 -0500" MODIFIED_BY="Chris Champion">
<P>Intervention 1: in the first group, during the two weeks titration phase, the Oxcarbazepine was started by 300 mg and increased every two days to a maximum dose of 900 to 2400 mg per days or the highest tolerated dose. Intervention 2: in the second group, Na Valporate was initiated by 600 mg/day and increased to a 20-36 mg/day or the highest tolerated dose for the participants.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change of mood. Timepoint: base line, weeks 3 and 6. Method of measurement: Young Mania rating scale</P>
<P>Secondary outcome: Clinical Global Impression Scale. Timepoint: base line, weeks 3 and 6. Method of measurement: change of scores</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]">
<P>4 July 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-10-15 06:19:39 -0400" MODIFIED_BY="[Empty name]">
<P>Dr Atefeh Soltanifar, soltanifara@mums.ac.ir</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-10-15 06:19:43 -0400" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-11-08 15:23:34 -0500" MODIFIED_BY="Chris Champion">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-11-08 15:23:32 -0500" MODIFIED_BY="Chris Champion" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990">
<DESCRIPTION>
<P>No method described for achieving blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990b">
<DESCRIPTION>
<P>No method described for achieving blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Juruena-2009">
<DESCRIPTION>
<P>The randomisation was computer generated by a "four-digit selection code&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 15:18:53 -0500" MODIFIED_BY="Chris Champion" RESULT="YES" STUDY_ID="STD-Kakkar-2009">
<DESCRIPTION>
<P>Reported as double blind in publication, no further details. However, on request, authors have clarified usage of "permuted block randomization" to ensure that number of participants allocated to each treatment group was well balanced. The details of the block size were not revealed to the study staff to protect the allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mueller-1984b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suppes-2007">
<DESCRIPTION>
<P>Each patient randomised to receive either oxcarbazepine or divalproex using an unspecified technique.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 15:23:32 -0500" MODIFIED_BY="Chris Champion" RESULT="YES" STUDY_ID="STD-Wagner-2006">
<DESCRIPTION>
<P>The publication mentions that a computer&#8208;generated randomisation list, stratified by age subgroup and comorbid ADHD was used to assign participants to each treatment group. On request, the study authors shared the protocol with the review authors. The protocol mentions use of a telephone based automatic randomised assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-03 10:38:03 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Juruena-2009">
<DESCRIPTION>
<P>Though not specified in the published report, clarification from author confirmed usage of sequentially numbered sealed envelopes and containers. Randomisation list was maintained centrally so no centre knew the treatment allocation of a patient.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kakkar-2009">
<DESCRIPTION>
<P>No documentation of allocation concealment in publication. However, on request, authors have clarified that allocation concealment was ensured with the help of opaque, well sealed and sequentially numbered identical envelopes. After assessing eligibility and consent, the participant details were recorded on the envelope and they were opened post- randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mueller-1984b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suppes-2007">
<DESCRIPTION>
<P>No description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wagner-2006">
<DESCRIPTION>
<P>The manuscript mentions that the randomisation schemes were reviewed by a Biostatistics Quality Assurance Group and locked after approval. Randomisation data were kept confidential and were accessible to authorised persons only. Only after double blind part of the study was completed, the drug codes were broken and data made available for analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-11-08 15:23:34 -0500" MODIFIED_BY="Chris Champion" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>of participants?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>of staff administering treatment?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>of outcome assessors?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990">
<DESCRIPTION>
<P>Quoted "double-blind". Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990b">
<DESCRIPTION>
<P>Quoted "double-blind". Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-03 10:38:00 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Juruena-2009">
<DESCRIPTION>
<P>Investigators describe the study as &#8220;double-blind&#8221;. No further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-03 10:37:57 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Juruena-2009">
<DESCRIPTION>
<P>Investigators describe the study as &#8220;double-blind&#8221;. No further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Juruena-2009">
<DESCRIPTION>
<P>Outcome assessors were also blinded. Methods of maintaining blind post-randomisation were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 15:22:29 -0500" MODIFIED_BY="Chris Champion" RESULT="YES" STUDY_ID="STD-Kakkar-2009">
<DESCRIPTION>
<P>Publication mentions double blinding. Clarification revealed that study medications were dispensed in the identical appearing capsules and both the drugs were dosed on twice daily basis. Blinded raters evaluated the participants with YMRS at each visit. Participants, raters, and investigators were all blind to<SUP> </SUP>the treatment assignments.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-03 10:36:55 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kakkar-2009">
<DESCRIPTION>
<P>The study mentions that the dose of medication was reduced if there were intolerable side effects. One patient on valproate had to have his medication lowered because of epistaxis related to thrombocytopenia. No detail is available how blinding was maintained during this.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kakkar-2009">
<DESCRIPTION>
<P>Though clarifications suggest that outcome assessors were blind, there is no explicit description of how this was maintained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mueller-1984b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mueller-1984b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mueller-1984b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 15:19:07 -0500" MODIFIED_BY="Chris Champion" RESULT="NO" STUDY_ID="STD-Suppes-2007">
<DESCRIPTION>
<P>Participants were not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suppes-2007">
<DESCRIPTION>
<P>No description in published account.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-08 15:19:15 -0500" MODIFIED_BY="Chris Champion" RESULT="UNKNOWN" STUDY_ID="STD-Suppes-2007">
<DESCRIPTION>
<P>The &#8220;rater was blind&#8221; and &#8220;discussion of participants and study was kept separate from staff meetings&#8221;. It is not clear what other steps were taken to maintain the blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 15:23:34 -0500" MODIFIED_BY="Chris Champion" RESULT="YES" STUDY_ID="STD-Wagner-2006">
<DESCRIPTION>
<P>The protocol mentions that clinical research associates, medical monitors, study site personnel, Novartis personnel responsible for the conduct and monitoring of the study, participants/parents or legal guardians did not know the assigned treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-06-02 08:24:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wagner-2006">
<DESCRIPTION>
<P>As above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-06-02 08:25:01 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wagner-2006">
<DESCRIPTION>
<P>As above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-11-08 15:23:16 -0500" MODIFIED_BY="Chris Champion" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990">
<DESCRIPTION>
<P>Insufficiently described in publication to allow a conclusion as to whether this was performed or not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990b">
<DESCRIPTION>
<P>Insufficiently described in publication to allow a conclusion as to whether this was performed or not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Juruena-2009">
<DESCRIPTION>
<P>Fifty-two participants were included and completed the study. Data analysis includes all 52 participants.</P>
<P>An intention-to-treat analysis was carried out.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kakkar-2009">
<DESCRIPTION>
<P>The study mentions that all 60 participants who completed randomisation were able to complete the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mueller-1984b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 15:23:16 -0500" MODIFIED_BY="Chris Champion" RESULT="NO" STUDY_ID="STD-Suppes-2007">
<DESCRIPTION>
<P>Thirteen of the 30 participants didn't complete this eight week study. Three had no follow-up visits, three others were lost to follow-up, three withdrew and four further participants had &#8220;worsening mood symptoms&#8221; and presumably were withdrawn from the trial. It is stated that the three participants who did not have any follow-up visits were excluded from efficacy analysis, The mean scores at endpoint included data from 27 participants - i.e. all except those three which suggests that LOCF were used. however this is not explicitly stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-10-13 05:46:35 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wagner-2006">
<DESCRIPTION>
<P>Intent&#8208;to&#8208;treat group clearly defined and accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-03 10:37:46 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Juruena-2009">
<DESCRIPTION>
<P>The published report includes all<BR/>expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-03 10:36:43 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kakkar-2009">
<DESCRIPTION>
<P>There is no comparison of pre-randomisation medications which could highlight differences in groups, if any.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mueller-1984b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-01 11:06:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suppes-2007">
<DESCRIPTION>
<P>Study seems to have reported most results as per protocol. However, protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-13 05:46:37 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wagner-2006">
<DESCRIPTION>
<P>Intent&#8208;to&#8208;treat group clearly defined and accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Emrich-1990b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-03 10:37:49 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Juruena-2009">
<DESCRIPTION>
<P>The study appears free of other<BR/>sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-03 10:36:28 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kakkar-2009">
<DESCRIPTION>
<P>All outcome data as per materials and methods were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mueller-1984b">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-04 04:33:19 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suppes-2007">
<DESCRIPTION>
<P>Authors acknowledge number of limitations of the study i.e. open-label treatment design, add-on study, small sample size and lack of double blinding. There was discrepancy between the text and the figures. It was difficult to ascertain if SD or SE were reported for the YMRS scale by visual inspection. We confirmed the values presented in the text to be SDs rather than SEs after clarification.</P>
<P>Authors also acknowledge that pharmaceutical manufacturer of oxcarbazepine provided funding for the research as well as editorial assistance for the manuscript.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-02 08:34:09 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wagner-2006">
<DESCRIPTION>
<P>The authors acknowledge that the study was conducted at 20 sites, which could have added significant variability to the results. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-11-08 15:13:43 -0500" MODIFIED_BY="Chris Champion">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-10-15 06:33:21 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-01-09 07:33:33 -0500" MODIFIED_BY="[Empty name]">Description of ICD and DSM codes</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TD>
<P>Description of condition</P>
</TD>
<TD>
<P>ICD codes</P>
</TD>
<TD>
<P>DSM codes</P>
</TD>
</TR>
<TR>
<TD>
<P>Hypomania or mania with or without psychotic symptoms</P>
</TD>
<TD>
<P>F30.0 and F31.0-31.2*</P>
</TD>
<TD>
<P>296.40 or 296.41-4*</P>
</TD>
</TR>
<TR>
<TD>
<P>Mixed affective disorder, with or without psychotic symptoms</P>
</TD>
<TD>
<P>F31.6*</P>
</TD>
<TD>
<P>296.61-4*</P>
</TD>
</TR>
<TR>
<TD>
<P>Depressive episodes, with or without psychotic symptoms </P>
</TD>
<TD>
<P>F31.3-31.5* </P>
</TD>
<TD>
<P>296.21-4 and 296.31-4*</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2011-11-08 15:13:43 -0500" MODIFIED_BY="Chris Champion" NO="2">
<TITLE MODIFIED="2010-06-14 05:45:15 -0400" MODIFIED_BY="[Empty name]">description of rating scales</TITLE>
<TABLE COLS="2" ROWS="10">
<TR>
<TD>
<P>Name of rating scale</P>
</TD>
<TD>
<P>Description</P>
</TD>
</TR>
<TR>
<TD>
<P>Bech and Refaelsen mania rating scale (BRMAS) <LINK REF="REF-Bech-1979" TYPE="REFERENCE">Bech 1979</LINK>
</P>
</TD>
<TD>
<P>This is an 11 item scoring scale: each symptom is measured from 0 to 4, increasing from not present to severe. The items included activity (motor and verbal), flight of thought, voice level, hostility/destructiveness, mood, self esteem, contact, sleep, sexual interest and work.</P>
</TD>
</TR>
<TR>
<TD>
<P>Young Mania Rating Scale (YMRS) <LINK REF="REF-Young-1978" TYPE="REFERENCE">Young 1978</LINK>
</P>
</TD>
<TD>
<P>This scale has 11 items which are rated after a clinical interview. Irritability, speech rate and amount, content of thought and disruptive behaviour items are given extra weight in the total by being scored from 0-8, whereas the remaining items are scored from 0-4. Higher scores indicate more symptoms.</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical Global Improvement (CGI) <LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>
</P>
</TD>
<TD>
<P>The scale assesses both severity of illness and clinical improvement by comparing the condition of the subject standardised against others with the same diagnosis. The seven point scoring system is usually employed, with low scores showing decreased severity and overall improvement.</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical Global Improvement, Bipolar Version (CGI-BP) <LINK REF="REF-Spearing-1997" TYPE="REFERENCE">Spearing 1997</LINK>
</P>
</TD>
<TD>
<P>This is a modified version of the scale which includes the correction of perceived inconsistencies in scaling, detailed definitions of illness severity and change, the inclusion of time frames and the separation of the assessment of improvement in illness from the assessment of the adverse effects of treatment. Previous phases of illness are also used as comparators for the assessed period. A CGI score of greater than three is often taken to indicate a clinical response.</P>
</TD>
</TR>
<TR>
<TD>
<P>Child Health Questionnaire (CHQ) <LINK REF="REF-Landgraf-1999" TYPE="REFERENCE">Landgraf 1999</LINK>
</P>
</TD>
<TD>
<P>The scale is a quality of life questionnaire which has both physical and psychosocial components. It assesses a child's physical, emotional, and social well-being from the perspective of a parent or guardian {CHQ-PF50 and PF-28 (short form)} or, in some instances, the child directly (CHQ-CF87, for children ten years of age and older). There are 14 domains, with scores aggregated to derive two summary component scores of physical and psychosocial health. Scores can then be transformed to a 0-100 scale.</P>
</TD>
</TR>
<TR>
<TD>
<P>Hamilton Depression Rating Scale-21 (HDRS) <LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>
</P>
</TD>
<TD>
<P>The HDRS (also known as the Ham-D) is a widely used clinician-administered depression assessment scale. The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past<BR/>week. The HDRS17 has 17 items which can be graded from 0 to 4 based on a semi structured interview. A later 21-item version (HDRS21) included four items for definition of subtype of depression.</P>
</TD>
</TR>
<TR>
<TD>
<P>Montgomery-Asberg Depression Rating Scale (MADRS) <LINK REF="REF-Montgomery-1979" TYPE="REFERENCE">Montgomery 1979</LINK>
</P>
</TD>
<TD>
<P>This scale is a 10 item depression rating score which has a fixed scaling of seven points (from 0 through 6). Compared to the HAM-D the MADRS is supposed to capture pure psychiatric symptoms better. The HAM-D and MADRS have been found to have high level of correlation with each other and hence they are both usually applied together.</P>
</TD>
</TR>
<TR>
<TD>
<P>Brief Psychiatric Rating Scale (BPRS) <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>
</P>
</TD>
<TD>
<P>The Brief Psychiatric rating scale (BPRS) assesses the level of 18 symptom constructs of psychosis such as hostility, suspicion, hallucination and grandiosity. It is based on the clinician's interview with the patient and observations of the patient's behavior over the previous 2&#8211;3 days.</P>
</TD>
</TR>
<TR>
<TD>
<P>Children's depression rating scale (CDRS) <LINK REF="REF-Poznaski-1984" TYPE="REFERENCE">Poznaski 1984</LINK>
</P>
</TD>
<TD>
<P>The Children&#8217;s Depression Rating Scale (CDRS) is a 16-item measure used to determine the severity of depression in children 6-12 years of age.Items are measured on 3-, 4-, 5-, and 6-point scales. The CDRS is derived from the Hamilton Rating Scale for Depression (HAM-D); a score of 15 on the CDRS is equivalent to a score of 0 on the HAM-D. Assessment information is based on parent, child and schoolteacher interviews.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2011-11-04 05:43:00 -0400" MODIFIED_BY="Chris Champion" NO="3">
<TITLE MODIFIED="2011-07-10 20:24:49 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Should this read 'N of comparison studies'?&lt;/p&gt;" NOTES_MODIFIED="2011-07-10 20:24:49 -0400" NOTES_MODIFIED_BY="[Empty name]">Side effect profile by body systems</TITLE>
<TABLE COLS="7" ROWS="60">
<TR>
<TD>
<P>
<B>Control Drug</B>
</P>
</TD>
<TD>
<P>
<B>Body System</B>
</P>
</TD>
<TD>
<P>
<B>Side Effects</B>
</P>
</TD>
<TD>
<P>
<B>N of Comparisons</B>
</P>
</TD>
<TD>
<P>
<B>N of Participants</B>
</P>
</TD>
<TD>
<P>
<B>Adverse event rate (%) in oxcarbazepine group</B>
</P>
</TD>
<TD>
<P>
<B>Adverse event rate (%) in comparison group</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Versus Placebo</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Neuropsychiatric</P>
</TD>
<TD>
<P>Dizziness</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>39.0</P>
</TD>
<TD>
<P>10.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Somnolence</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>20.3</P>
</TD>
<TD>
<P>3.6</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Diplopia</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>18.6</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Fatigue</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>16.9</P>
</TD>
<TD>
<P>7.1</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Dermatological</P>
</TD>
<TD>
<P>Rash</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P>1.8</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Gastrointestinal</P>
</TD>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>30.5</P>
</TD>
<TD>
<P>10.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Psychiatric- leading to</P>
<P>hospital admission</P>
</TD>
<TD>
<P>exacerbation of bipolar disorder</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>5.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>aggressive outburst</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>1.8</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>suicide attempt</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>1.8</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>inappropriate sexual behaviour</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>115</P>
</TD>
<TD>
<P>1.8</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Versus Haloperidol</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Neuropsychiatric</P>
</TD>
<TD>
<P>Muscular stiffness</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>10.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Apathy</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>5.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lack of co-ordination</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>5.8</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Nervousness</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>5.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Parkinsonian symptoms</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>5.8</P>
</TD>
<TD>
<P>10.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Acute dystonia</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>5.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Extrapyramidal symptoms</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>5.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Eye cramps</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>5.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Genito-urinary</P>
</TD>
<TD>
<P>Loss of libido</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>5.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Endocrine</P>
</TD>
<TD>
<P>Lactation</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>5.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Gastrointestinal</P>
</TD>
<TD>
<P>Vomiting</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>5.8</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Versus Lithium</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Cardiovascular</P>
</TD>
<TD>
<P>Hypotension</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>6.9</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Gastrointestinal</P>
</TD>
<TD>
<P>Dysphagia</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>3.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Heartburn</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>3.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Neuropsychiatric</P>
</TD>
<TD>
<P>Depression</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Vertigo</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Parkinsonian symptoms</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Sleep disturbance</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Oculogyric crisis</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Slurred speech</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Hypokinesia</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>3.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Muscular stiffness</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>3.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Akathisia</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>3.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Lack of co-ordination</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>3.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Somnolence</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>3.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Tremor</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>3.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>Sialorrhea</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>6.9</P>
</TD>
<TD>
<P>3.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Hypersalivation</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>3.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Dermatological</P>
</TD>
<TD>
<P>Skin rash</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Versus Valproate</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Neuropsychiatric</P>
</TD>
<TD>
<P>Dizzines</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P>23.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P>20.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Sedation</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P>16.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Gastrointestinal</P>
</TD>
<TD>
<P>Nausea</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>16.7</P>
</TD>
<TD>
<P>23.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Vomiting</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>13.3</P>
</TD>
<TD>
<P>20.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Increased appetite</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>10.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Pain abdomen</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>16.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Dyspepsia</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P>10.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Constipation</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>10.0</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Diarrhoea</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>6.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Oral</P>
</TD>
<TD>
<P>Dry mouth</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>3.3</P>
</TD>
<TD>
<P>6.7</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Blood</P>
</TD>
<TD>
<P>Thrombocytopenia</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>3.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Dermatological</P>
</TD>
<TD>
<P>Rash</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>3.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Alopecia</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>3.3</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Others</P>
</TD>
<TD>
<P>Weight gain</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>13.3</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Versus Carbamazepine</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Data not extractable</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-11-08 15:15:11 -0500" MODIFIED_BY="Chris Champion">
<COMPARISON ID="CMP-001" MODIFIED="2011-11-08 15:14:35 -0500" MODIFIED_BY="Chris Champion" NO="1">
<NAME>oxcarbazepine versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 02:32:33 -0400" MODIFIED_BY="Chris Champion" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="7.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>clinical response- categorical outcome, at least 50% reduction in YMRS</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oxcarbazepine</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.728869428821162" CI_START="0.9369362342954969" EFFECT_SIZE="2.1049107142857144" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="14" LOG_CI_END="0.6747573226588326" LOG_CI_START="-0.02828996518046381" LOG_EFFECT_SIZE="0.3232336787391844" MODIFIED="2011-02-22 07:59:25 -0500" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.4129734570170045" STUDY_ID="STD-Wagner-2006" TOTAL_1="55" TOTAL_2="55" VAR="0.17054707620057566" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 08:25:32 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="13.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="34" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>clinical response - categorical outcome, at least 50% reduction in YMRS, children</NAME>
<GROUP_LABEL_1>oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxcarbazepine</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.298946277057622" CI_START="1.1114675362414654" EFFECT_SIZE="3.3833333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="1.0127927927178682" LOG_CI_START="0.04589678234127048" LOG_EFFECT_SIZE="0.5293447875295693" MODIFIED="2011-04-01 08:06:42 -0400" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.5679595027076558" STUDY_ID="STD-Wagner-2006" TOTAL_1="34" TOTAL_2="35" VAR="0.32257799671592774" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-12 03:13:49 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="21" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>clinical response- categorical outcome, at least 50% reduction in YMRS,adolescents</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxcarbazepine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.902704544786811" CI_START="0.3242943413922039" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.5913656741545108" LOG_CI_START="-0.48906062925974825" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2011-02-22 08:07:10 -0500" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.6346477588219923" STUDY_ID="STD-Wagner-2006" TOTAL_1="21" TOTAL_2="20" VAR="0.40277777777777773" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2011-09-28 08:44:30 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.95" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>adjusted mean change in YMRS from baseline to endpoint</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2720994350586759" CI_START="-0.4759044859921519" EFFECT_SIZE="-0.101902525466738" ESTIMABLE="YES" MEAN_1="-10.9" MEAN_2="-9.79" MODIFIED="2010-03-25 07:47:45 -0400" MODIFIED_BY="[Empty name]" ORDER="79" SD_1="11.02" SD_2="10.61" SE="0.19082083317626938" STUDY_ID="STD-Wagner-2006" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2011-11-08 15:14:35 -0500" MODIFIED_BY="Chris Champion" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.95" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>adjusted mean change in children's depression rating scale from baseline to endpoint</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2262614750115655" CI_START="-0.5223003292441516" EFFECT_SIZE="-0.14801942711629304" ESTIMABLE="YES" MEAN_1="-7.92" MEAN_2="-6.44" MODIFIED="2010-03-25 07:47:45 -0400" MODIFIED_BY="[Empty name]" ORDER="80" SD_1="10.21" SD_2="9.64" SE="0.19096315293553276" STUDY_ID="STD-Wagner-2006" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2011-09-28 02:33:09 -0400" MODIFIED_BY="Chris Champion" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.84" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>adjusted mean change in CGI-S to endpoint</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.17902476793631955" CI_START="-0.5703286884114525" EFFECT_SIZE="-0.19565196023756642" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.1" MODIFIED="2010-03-25 07:47:45 -0400" MODIFIED_BY="[Empty name]" ORDER="81" SD_1="1.43" SD_2="1.61" SE="0.19116510871081724" STUDY_ID="STD-Wagner-2006" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2011-09-28 02:33:14 -0400" MODIFIED_BY="Chris Champion" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.84" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>adjusted mean change in CHQ, global health score</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6557196575374711" CI_START="-0.09557248097915788" EFFECT_SIZE="0.2800735882791566" ESTIMABLE="YES" MEAN_1="-2.82" MEAN_2="-8.03" MODIFIED="2010-03-25 07:47:45 -0400" MODIFIED_BY="[Empty name]" ORDER="82" SD_1="18.79" SD_2="18.15" SE="0.19165967957644262" STUDY_ID="STD-Wagner-2006" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2011-09-28 02:33:21 -0400" MODIFIED_BY="Chris Champion" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.65" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="55" TOTAL_2="55" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>adjusted mean change in CHQ; global behaviour score</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.30705346782197845" CI_START="-0.44066368314653653" EFFECT_SIZE="-0.06680510766227904" ESTIMABLE="YES" MEAN_1="9.83" MEAN_2="11.78" MODIFIED="2010-03-25 07:47:45 -0400" MODIFIED_BY="[Empty name]" ORDER="83" SD_1="29.58" SD_2="28.38" SE="0.1907476761987497" STUDY_ID="STD-Wagner-2006" TOTAL_1="55" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-29 08:25:32 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.88" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="59" TOTAL_2="56" WEIGHT="0.0" Z="0.0">
<NAME>Total drop out rate from baseline to endpoint (more events:poorer outcome)</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>oxcarbazepine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.455406432777231" CI_START="0.3212358157334318" EFFECT_SIZE="0.6837606837606838" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.16298429013571508" LOG_CI_START="-0.49317603964415113" LOG_EFFECT_SIZE="-0.16509587475421805" MODIFIED="2011-02-22 08:18:15 -0500" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.38543182575870966" STUDY_ID="STD-Wagner-2006" TOTAL_1="59" TOTAL_2="56" VAR="0.1485576923076923" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-11-08 15:15:11 -0500" MODIFIED_BY="Chris Champion" NO="2">
<NAME>oxcarbazepine versus other mood stabilisers</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-28 02:33:41 -0400" MODIFIED_BY="Chris Champion" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>clinical response-categorical outcome, at least 50% reduction in YMRS</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Valproate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxcarbazepine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.974005848056067" CI_START="0.10006599747009488" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" LOG_CI_END="0.29534843494695007" LOG_CI_START="-0.9997134711696749" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2011-04-02 15:00:22 -0400" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.7607257743127307" STUDY_ID="STD-Kakkar-2009" TOTAL_1="30" TOTAL_2="30" VAR="0.5787037037037037" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.8368662867827374" CI_END="0.5926665942766299" CI_START="-0.23754851364224175" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.17755904031719408" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2011-10-12 03:15:35 -0400" MODIFIED_BY="Chris Champion" NO="2" P_CHI2="0.3602946267195575" P_Q="1.0" P_Z="0.40182888678953466" Q="0.0" RANDOM="NO" SCALE="1.19" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="45" UNITS="" WEIGHT="100.0" Z="0.838359410306475">
<NAME>mean change in YMRS score from baseline to endpoint: Change score (decrease=good)</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Valproate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Valproate</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8368662867827374" CI_END="0.5926665942766299" CI_START="-0.23754851364224175" DF="1" EFFECT_SIZE="0.17755904031719408" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" MODIFIED="2011-03-29 06:22:22 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3602946267195575" P_Z="0.40182888678953466" STUDIES="2" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="0.838359410306475">
<NAME>Oxcarbazepine versus valproate</NAME>
<CONT_DATA CI_END="0.8247964699018608" CI_START="-0.19403641631897295" EFFECT_SIZE="0.31538002679144395" ESTIMABLE="YES" MEAN_1="-22.76" MEAN_2="-24.63" MODIFIED="2011-03-29 06:11:25 -0400" MODIFIED_BY="[Empty name]" ORDER="115" SD_1="5.46" SD_2="6.22" SE="0.2599111244536271" STUDY_ID="STD-Kakkar-2009" TOTAL_1="30" TOTAL_2="30" WEIGHT="66.40111236602456"/>
<CONT_DATA CI_END="0.6213253598983101" CI_START="-0.8109554809882545" EFFECT_SIZE="-0.09481506054497227" ESTIMABLE="YES" MEAN_1="-13.27" MEAN_2="-12.43" MODIFIED="2011-03-29 06:22:22 -0400" MODIFIED_BY="[Empty name]" ORDER="116" SD_1="7.81" SD_2="9.36" SE="0.36538447955784215" STUDY_ID="STD-Suppes-2007" TOTAL_1="15" TOTAL_2="15" WEIGHT="33.59888763397543"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2011-10-15 05:53:38 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.39" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>mean change in CGI-S scores by end of study: Change score (decrease=good)</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Valproate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Valproate</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.01" MODIFIED="2011-03-29 06:28:25 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Oxcarbazepine versus valproate</NAME>
<CONT_DATA CI_END="0.23577620126818566" CI_START="-1.220321896601552" EFFECT_SIZE="-0.4922728476666832" ESTIMABLE="YES" MEAN_1="-2.08" MEAN_2="-1.25" MODIFIED="2011-03-29 06:28:25 -0400" MODIFIED_BY="[Empty name]" ORDER="119" SD_1="1.6" SD_2="1.68" SE="0.37146042206776597" STUDY_ID="STD-Suppes-2007" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-08 15:15:11 -0500" MODIFIED_BY="Chris Champion" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>categorical outcome, physician evaluation of tolerability: Good (good to excellent)</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Lithium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lithium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oxcarbazepine</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.612086620823723" CI_START="0.29490661354648384" EFFECT_SIZE="1.9285714285714286" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="1.1007869448554877" LOG_CI_START="-0.5303154878939891" LOG_EFFECT_SIZE="0.2852357284807493" MODIFIED="2011-04-02 15:07:47 -0400" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.958117643084302" STUDY_ID="STD-Emrich-1990b" TOTAL_1="29" TOTAL_2="24" VAR="0.9179894179894179" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-15 05:53:38 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>categorical outcome, physician global evaluation of tolerability: Poor (moderate to poor)</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Lithium</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Lithium</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.261426833508747" CI_START="0.1060338482099063" EFFECT_SIZE="0.8148148148148148" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7966733100970681" LOG_CI_START="-0.9745554767706304" LOG_EFFECT_SIZE="-0.0889410833367811" MODIFIED="2011-04-02 15:15:41 -0400" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="1.040428557129985" STUDY_ID="STD-Emrich-1990b" TOTAL_1="29" TOTAL_2="24" VAR="1.0824915824915824" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-10-15 05:54:01 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Oxcarbazepine as an adjunctive mood stabiliser vs alternative mood stabiliser</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2011-10-15 05:54:01 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.33" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean change in YMRS score from baseline to endpoint: Change score (decrease=good)</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Carbamazepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours carbamazepine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.22228290303164988" CI_START="-0.872656388937309" EFFECT_SIZE="-0.32518674295282957" ESTIMABLE="YES" MEAN_1="-9.2" MEAN_2="-6.8" MODIFIED="2011-10-15 05:51:24 -0400" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="8.2" SD_2="6.2" SE="0.27932638063905774" STUDY_ID="STD-Juruena-2009" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2011-10-15 05:54:01 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.23" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>mean change in MADRS score by endpoint: Change score (decrease=good)</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Carbamazepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Carbamazepine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5311071454900551" CI_START="-1.706748762427151" EFFECT_SIZE="-1.118927953958603" ESTIMABLE="YES" MEAN_1="-12.0" MEAN_2="-6.2" MODIFIED="2011-10-15 05:52:40 -0400" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="5.8" SD_2="4.3" SE="0.2999140867409827" STUDY_ID="STD-Juruena-2009" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2011-10-15 05:54:01 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.7" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>mean change in HDRS by end of study: Change score (decrease=good)</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Carbamazepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Carbamazepine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.2028344578826614" CI_START="-1.3325239765171943" EFFECT_SIZE="-0.7676792171999278" ESTIMABLE="YES" MEAN_1="-12.2" MEAN_2="-6.1" MODIFIED="2011-10-15 05:52:46 -0400" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="6.3" SD_2="9.1" SE="0.2881913972770366" STUDY_ID="STD-Juruena-2009" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2011-10-15 05:54:01 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.44" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean change in CGI-S Scores by end of study period: Change score (decrease=good)</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Carbamazepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours carbamazepine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5867737405150846" CI_START="-1.7718098688102868" EFFECT_SIZE="-1.1792918046626857" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-1.0" MODIFIED="2011-10-15 05:52:56 -0400" MODIFIED_BY="[Empty name]" ORDER="26" SD_1="0.7" SD_2="0.8" SE="0.3023106897990514" STUDY_ID="STD-Juruena-2009" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2011-10-15 05:54:01 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.18" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>mean change in CGI-I score by end of study: Change score (decrease=good)</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Carbamazepine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Carbamazepine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.01" MODIFIED="2011-10-15 05:53:11 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Oxcarbazepine versus carbamazepine</NAME>
<CONT_DATA CI_END="-0.5659969684817826" CI_START="-1.7474736450836827" EFFECT_SIZE="-1.1567353067827326" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-0.9" MODIFIED="2011-10-15 05:53:11 -0400" MODIFIED_BY="[Empty name]" ORDER="27" SD_1="0.9" SD_2="0.8" SE="0.3014026497224534" STUDY_ID="STD-Juruena-2009" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-10-30 13:55:25 -0400" MODIFIED_BY="Chris Champion" NO="4">
<NAME>oxcarbazepine versus antipsychotics</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-15 06:53:58 -0400" MODIFIED_BY="Chris Champion" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="230.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="17" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>physician global evaluation of tolerability</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Haloperidol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="15" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-02-22 08:25:36 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>physician global evaluation of tolerability, good to excellent</NAME>
<DICH_DATA CI_END="51.09102926831893" CI_START="0.5567404855960219" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="1.70834465196879" LOG_CI_START="-0.2543471960962653" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2011-02-22 08:25:36 -0500" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="1.1528949070347507" STUDY_ID="STD-Emrich-1990" TOTAL_1="17" TOTAL_2="20" VAR="1.3291666666666666" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-10-30 13:55:25 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="452.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="17" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Physician global evaluation of tolerability, moderate to poor</NAME>
<GROUP_LABEL_1>Oxcarbazepine</GROUP_LABEL_1>
<GROUP_LABEL_2>Haloperidol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oxcarbazepine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours haloperidol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7961689977143371" CI_START="0.019572907696735142" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.25434719609626527" LOG_CI_START="-1.70834465196879" LOG_EFFECT_SIZE="-0.7269987279362623" MODIFIED="2011-02-22 08:27:56 -0500" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="1.1528949070347507" STUDY_ID="STD-Emrich-1990" TOTAL_1="17" TOTAL_2="20" VAR="1.3291666666666666" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-11-08 15:23:35 -0500" MODIFIED_BY="Chris Champion">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-11-08 08:34:15 -0500" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-11-08 15:23:35 -0500" MODIFIED_BY="Chris Champion" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-11-08 15:23:35 -0500" MODIFIED_BY="Chris Champion" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-10-31 12:45:30 -0400" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-10-31 12:45:30 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-12-01 11:40:40 -0500" MODIFIED_BY="[Empty name]">Search strategies used in review</TITLE>
<APPENDIX_BODY MODIFIED="2011-10-31 12:45:30 -0400" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="1">
<TR>
<TD VALIGN="TOP">
<P>
<B>MEDLINE</B>
</P>
<P>1 randomized controlled trial.pt.</P>
<P>2 controlled clinical trial.pt.</P>
<P>3 randomi#ed.ab.</P>
<P>4 placebo$.ab.</P>
<P>5 drug therapy.fs.</P>
<P>6 randomly.ab.</P>
<P>7 trial.ab.</P>
<P>8 groups.ab.</P>
<P>9 or/1-8</P>
<P>10 (animals not (humans and animals)).sh.</P>
<P>11 9 not 10</P>
<P>12 bipolar disorder/ [MeSH]</P>
<P>13 bipolar adj3 disorder$.ti,ab.</P>
<P>14 (mania$ or manic$).ti,ab.</P>
<P>15 (bipolar affective adj1 psychosis).ti,ab.</P>
<P>16 or/12-15</P>
<P>17 oxcarbazepin$.tw.</P>
<P>18 (trileptal or timox or apydan or GP 47680 or CO36006).tw.</P>
<P>19 28721-07-5.rn.</P>
<P>20 or/17-19</P>
<P>21 11 and 16 and 20</P>
<P>
<B> </B>
</P>
<P>
<B>EMBASE</B>
</P>
<P>1 random$.tw.</P>
<P>2 factorial$.tw.</P>
<P>3 crossover$.tw.</P>
<P>4 cross over$.tw.</P>
<P>5 placebo$.tw.</P>
<P>6 (doubl$ adj blind$).tw.</P>
<P>7 (singl$ adj blind$).tw.</P>
<P>8 assign$.tw.</P>
<P>9 allocat$.tw.</P>
<P>10 volunteer$.tw.</P>
<P>11 crossover-procedure.de.</P>
<P>12 double-blind procedure.de.</P>
<P>13 randomized controlled trial.de.</P>
<P>14 single-blind procedure.de.</P>
<P>15 or/1-14</P>
<P>16 ((animal or nonhuman) not (human and (animal or nonhuman))).de.</P>
<P>17 15 not 16</P>
<P>18 exp bipolar disorder/<BR/>[bipolar depression, bipolar I disorder, bipolar II disorder, bipolar mania, cyclothymia, manic depressive psychosis, mixed mania and depression, rapid cycling bipolar disorder]</P>
<P>19 bipolar adj3 disorder$.ti,ab.</P>
<P>20 (mania$ or manic$).ti,ab.</P>
<P>21 (bipolar affective adj1 psychosis).ti,ab.</P>
<P>22 or/18-21</P>
<P>23 oxcarbazepine/</P>
<P>24 oxcarbazepin$.tw.</P>
<P>25 (trileptal or timox or apydan or GP 47680 or CO36006).tw.</P>
<P>26 28721-07-5.rn.</P>
<P>27 or/23-26</P>
<P>28 17 and 22 and 27</P>
<P/>
<P>
<B>PsycINFO</B>
</P>
<P>1 treatment effectiveness evaluation.de.</P>
<P>2 clinical trials.de.</P>
<P>3 placebo.de.</P>
<P>4 treatment outcomes.de.</P>
<P>5 mental health program evaluation.de.</P>
<P>6. evaluation.de.</P>
<P>7. followup studies.de.</P>
<P>8. random$.tw.</P>
<P>9. placebo$.tw.</P>
<P>10 comparative stud$.tw.</P>
<P>11 (clinical adj3 trial$).tw.</P>
<P>12 (research adj3 design).tw.</P>
<P>13 (evaluat$ adj3 stud$).tw.</P>
<P>14. (prospectiv$ adj3 stud$).tw.</P>
<P>15 ((singl$ or doubl$ or tripl$) adj3 (blind$ or mask$ or dummy)).tw.</P>
<P>16 or/1-15</P>
<P>17 (animal NOT (animal and (human or inpatient or outpatient))).po.</P>
<P>18. 16 not 17</P>
<P>19 exp bipolar disorder/<BR/>    [cyclothymic personality]</P>
<P>20 (bipolar adj3 disorder$).ti,ab.</P>
<P>21 (bipolar affective adj1 psychosis).ti,ab.</P>
<P>22 exp mania/<BR/>     [hypomania]</P>
<P>23 (mania$ or manic$).ti,ab.</P>
<P>24 or/19-23</P>
<P>25 oxcarbazepin$.tw.</P>
<P>26 (trileptal or timox or apydan or GP 47680 or CO36006).tw.</P>
<P>27 or/25-26</P>
<P>28 18 and 24 and 27</P>
<P/>
<P>
<B>CENTRAL</B>
</P>
<P>#1 oxcarbazepin*</P>
<P>#2 Apydan or Trileptal</P>
<P>#3 (#1 OR #2)</P>
<P>#4 bipolar*</P>
<P>#5 mania* or manic* or hypomani*</P>
<P>#6 (#4 OR #5)</P>
<P>#7 (#3 AND #6)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies included in quantitative synthesis&lt;br&gt;(efficacy meta-analysis)&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="140">
<FLOWCHARTBOX TEXT="&lt;p&gt;57 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="145">
<FLOWCHARTBOX TEXT="&lt;p&gt;186 records screened&lt;/p&gt;" WIDTH="142">
<FLOWCHARTBOX TEXT="&lt;p&gt;186 records after duplicates removed&lt;/p&gt;" WIDTH="240">
<FLOWCHARTBOX TEXT="&lt;p&gt;186 records identified through database searching (MEDLINE, EMBASE, PsycINFO, CENTRAL, CCDANCTR)&lt;/p&gt;" WIDTH="210"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="190"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;129 records excluded&lt;/p&gt;" WIDTH="137"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;50 full-text articles excluded&lt;/p&gt;" WIDTH="115"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>